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Abstract 
Background: This study evaluates a new serum-based biomarker for colorectal 
cancer (CRC) screening and diagnosis. The biomarker (GTA-446) is a member of 
hydroxy -polyunsaturated ultra-long chain fatty acids and was found to be reduced in 
CRC patients compared to CRC-free subjects. Diagnostic test performance characteristics 
were used to identify the effectiveness of the test. 
Methods: Serum levels of GTA-446 were measured in 4924 subjects who 
underwent colonoscopy for any reason, pathology results and clinical data were also 
collected. Two sets of age-matched control subjects were used; First were the lab controls 
(number=383) which were serum samples collected from Saskatchewan Disease Control 
Laboratory along with age and gender data. Second, were the endoscopy controls 
(number=762) which were obtained from the colonoscopy population after being 
determined to be cancer-free. Cut-off values were calculated using  Receiver Operating 
Characteristic (ROC) curve. 
          Results: Serum GTA-446 was found to be reduced in 87% of CRC patients. 
Compared to lab controls, the GTA-446 biomarker has a sensitivity of 87%, specificity of 
75%, positive likelihood ratio of 3.6, and negative likelihood ratio of 0.16. Using 
endoscopy controls to calculate test performance characteristics, the biomarker has a 
sensitivity of 87%, specificity of 50%, positive likelihood ratio of 1.74, and negative 
likelihood ratio of 0.24. Also, the level of GTA-446 was found to significantly decline 
with age (r=-0.20, p<0.01). 
        Conclusion: Serum GTA-446 is a potential biomarker for minimally invasive 
detection of colorectal cancer that compares favorably to other serum-based biomarkers.  
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1 Epidemiology and Pathogenesis: 
Colorectal cancer is the third most common cancer in Canada with age 
standardized incidence rate of 61 per 100 000 males and 40 per 100 000 females and is 
the second leading cause of cancer death in Canada. Despite improvements in surgical 
and chemotherapeutic treatments, colorectal cancer has a poor 5-y survival rate of 63% 
for males and 64% for females (1). Identifying modifiable factors associated with 
colorectal cancer is of importance, the ultimate goal being primary prevention (2). 
Approximately 95% of the malignant colorectal tumors are adenocarcinomas with 
the majority arising  from adenomas. It takes several years for an adenoma to progress to 
a carcinoma. The progression to cancer results from the accumulation of multiple genetic 
changes. Not all adenomas progress to cancer. In fact, the vast majority of adenomas do 
not progress to carcinoma. The malignant potential of the adenomas has been correlated 
to their size, histopathology, and degree of dysplasia (3). 
 
 
2 Acquired Causes Of Colorectal Cancer: 
The risk of developing colorectal cancer (CRC) is influenced by both 
environmental and genetic factors. Acquired risk factors include the following categories: 
dietary factors, lifestyle factors, side-effects of medical interventions, and  comorbid 
medical conditions (4). 
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2.1 Dietary Factors 
The proportion of colorectal cancers attributed to dietary factors has been 
estimated to be about 50% (5). Further, approximately 66-77% of colorectal cancers have 
been suggested to be preventable by an appropriate combination of diet and physical 
activity (6). 
 
2.1.1 Consumption of Fat and colorectal cancer  
The association between total dietary fat and risk of colorectal cancer has been 
evaluated in numerous epidemiologic studies. Results from these analytic studies have 
generally been mixed. Whereas some studies have reported positive associations, several 
studies have observed null and inverse associations. In a pooled analysis of data from 13 
case control studies, no evidence of risk to CRC was found after adjustment for total 
energy intake (7). Moreover, results for total dietary fat across several prospective cohort 
studies have not been supportive of a significant positive association with CRC (8), 
although a statistically significant 2-fold association was found in an analysis of women 
in the Nurses' Health Study (9).  
It is becoming apparent that the type of fat should be considered, as well as total 
fat intake. Total fat consists of different fatty acid families, e.g., saturated fatty acids 
(SFAs), monounsaturated fatty acids (MUFAs), n-3 and n-6 polyunsaturated fatty acids 
(PUFAs) and conjugated fatty acids (CFAs). Plant fats have higher concentrations of 
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unsaturated fatty acids and tend to be oils, whereas animal fats consist of larger amounts 
of saturated fatty acids as well as unsaturated fats (10).  
Experimental studies have confirmed beneficial and harmful effects of fatty acids 
on abnormal cell proliferation in colon cancer. In colon cancer, animal experiments and 
cell culture studies have shown that n-3 PUFAs and CFAs were beneficial. While n-6 
PUFAs were harmful; SFAs were ineffective, and MUFA action was inconclusive. In 
particular, the dietary doses required for tumor suppression by CFAs were strikingly low 
(<1%) in comparison to the doses required to achieve tumor suppression with  n-3PUFAs 
(5-10%) (11;12). However, few epidemiological human studies have investigated the 
relationship between CFA intake or tissue CFA concentrations and tumor incidence. A 
prospective study investigating the effect of conjugated linoleic acid intake as estimated 
by food questionnaire on the incidence of breast cancer showed no protective effect on 
cancer development (13).  
The confirmed effect of n-6 and n-3 PUFAs on colorectal cancer development in 
experimental studies was not reproduced in human studies, especially those using food 
frequency questionnaires to assess PUFAs intake. Also, these studies did not adjust for 
other confounders that modify and oppose the effect of individual fatty acids. Such 
modifiers could be luminal e.g., Ca and fiber that interfere with the action of fatty acids 
on colon cells or genetic e.g., genes responsible for repair of damage induced by  fatty 
acids (7).  
In humans, the amount and rate of intake of specific fatty acids are hard to 
measure. In experimental animals the exact amount of purified fatty acid consumed can 
be monitored over a desired period. In contrast, humans consume many different kinds of 
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fatty acids in their diet, a mixture of which may exert opposite effects and contain highly 
variable amounts of crude fats with unknown purity.  A recent large case-control study 
tried to minimize these problems, and found a moderately strong inverse and dose 
dependent association in multivariate logistic regression models between colorectal 
cancer risk and intake of n-3 PUFAs and its main compounds (14). 
Recently, a study based its assessment on validated plasma markers for fatty acids 
such as the concentration of n-3 PUFAs in erythrocyte membrane (15). These studies 
confirmed that higher levels of n-3 PUFAs are associated with lower cancer risk. These  
results were confirmed by the recently published huge European Prospective 
Investigation into cancer and nutrition (N = 478,040 men and women) and the U.S.-based 
Physicians Health Study (N = 22,071 men) (16).  
   
Generally, the proposed mechanisms by which n-3 PUFAs and n-6 PUFAs affect 
carcinogenesis are that n-6 fatty acids and their derivatives promote the production of 
pro-inflammatory eicosanoids, whereas n-3 fatty acids suppress this action (17).  PUFAs 
are the basic constituents of membrane phospholipids and the production of eicosanoids 
begins with the liberation of PUFA from membrane phospholipids. The major PUFA in 
the cell membrane is Arachidonic acid [(AA; 20 carbons:4 double bonds, location of first 
double bond at C6 from the methyl terminal (AA, 20:4n-6)], and both n-3 PUFAs and 
CFA may compete with AA to block its incorporation into membrane phospholipids or to 
inhibit the cyclooxygenase(COX) and/or the lipooxygenase(LOX) pathway, leading to 
reduction in AA-derived eicosanoids. COX and LOX inhibitors efficiently block cell 
proliferation and induce apoptosis in colon cancer cells (10).   
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2.1.2 Fruits and vegetables:  
Fruits and vegetable intake have been suggested to be associated with reduced 
risk of many cancers. Several mechanisms have been hypothesized. The constituents of 
fruits and vegetables, including fiber, micronutrients (such as carotenoids, phenolics, 
isoflavonoids, isothiocyanates and indoles) demonstrate a range of physiological 
properties, including anticarcinogenic effects. In particular, the phytochemicals have been 
reported to induce detoxification enzymes, scavenge free radicals, alleviate inflammation, 
inhibit malignant transformation, stimulate immune functions and regulate the growth of 
cancer cells (18;19).  
Associations between the consumption of fruit and vegetables and CRC risk have 
been the focus of a large number of case-control and cohort studies. Nevertheless, a 
recent review by an international panel of experts concluded that the evidence for an 
inverse association between CRC risk and higher fruit and vegetables is limited; 
therefore, further studies are warranted. Discrepancies in the cumulative results to date 
may be explained by differences in study design and the susceptibility of case-control 
studies to recall and selection biases (20).  
           A large prospective collaborative project carried out in 10 different European 
countries: The European Prospective Investigation of Cancer and nutrition (EPIC) study; 
investigated how the consumption of total fruit and vegetables is related to CRC risk. The 
study included 452,755 subjects who completed a dietary questionnaire and were 
followed up for an average of 8.8 years. They found that consumption of fruits and 
vegetables was inversely associated with CRC, however this association is moderate  
( HR:0.86 for the highest vs the lowest quintile) (21).    
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It was hypothesized that not all fruits and vegetables show the ability to suppress 
carcinogenesis, and there may be specific subtypes of fruits and vegetables that exhibit 
anticarcinogenic effects. Recently, cruciferous vegetables, rather than vegetables as a 
group, have drawn a great deal of attention in cancer research because of their potential 
protective properties. Cruciferous vegetables, including broccoli, cabbage and 
cauliflower have been identified as rich sources of carotenoids, vitamin C, folate and 
soluble fiber, which may play an important role in cancer prevention. In addition, the 
ability of cruciferous vegetables to protect against neoplastic diseases has been attributed 
to their high glucosinolate content. Glucosinolates are converted by myrosinase in plant 
cells and microflora in the gastrointestinal tract to indole-carbinol and isothiocyanate, two 
phytochemicals that exhibit anticarcinogenic effects in models of animal cancer (22).  
In a multi-centre Japanese study, inverse associations were found in the group 
with the highest consumption of broccoli (OR 0.18) for the risk of colorectal cancer (23). 
In more recent studies the associations have been less consistent. In the case control 
studies, a significant inverse association was detected (OR 0.73), whereas in the cohort 
studies, no overall association with cruciferous vegetable intake was detected (OR 0.96). 
From the currently available data, it cannot be definitively concluded that the 
consumption of cruciferous vegetables is associated with the overall risk of colorectal 
cancer (24). 	  
   
Another approach to investigating the role of fruits and vegetables in risk of CRC 
is through an examination of dietary patterns rather than focusing on a single diet, 
because isolating single nutritional agents from diet is impossible. Dietary pattern 
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analysis reflects both nutrient/food group intakes and the types of foods that tend to be 
consumed together in the usual diet and may therefore provide additional insights into the 
diet and colon cancer relationship in a number of ways; 1) it takes into account the 
combined effects of foods, 2) there are likely racial/ethnic differences in dietary patterns 
that may contribute to variations in risk, 3) humans consume meals that include a variety 
of foods and not individual nutrients, and 4) patterns are more amenable to translation 
into dietary recommendations (25).  
A cohort study was conducted to assess the usual dietary intake of nearly 300,000 
men and 200,000 women by use of food frequency questionnaires. The individuals were 
then followed for up to 5 years to determine association of diet patterns with incidence of 
colorectal cancer. The authors applied a statistical technique called cluster analysis to 
identify groups of individuals with similar dietary patterns. Clusters of individuals were 
identified who ate higher quantities of fruit and vegetables, or diet foods and lean meats, 
or fatty meats. The largest cluster in both men and women was termed the "many foods" 
cluster, which contained a suboptimal profile of nutritional intake—this cluster served as 
the reference group. After controlling for other colorectal cancer risk factors, such as 
BMI, physical activity and smoking, the authors found that men in the "fruit and 
vegetable" cluster (characterized by a high intake of fruit and vegetables and a low intake 
of red meat), had a statistically significant 15% lower risk of colorectal cancer than 
individuals in the "many foods" cluster. Women in the "fruit and vegetable" cluster had a 
non-statistically significant 10% reduction in colorectal cancer risk compared with those 
in the "many foods" cluster (26). Another case control study conducted score analysis on 
three different dietary patterns; "Western-Southern", "fruit-vegetable", and 
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"metropolitan". The "fruit-vegetable" pattern was significantly inversely associated with 
colon cancer risk compared to "Western-Southern" pattern (OR 0.4) followed by 
"metropolitan" pattern (27).  
However, most studies conducted are based on a food frequency questionnaire 
which is prone to measurement and recall bias as cases may recall dietary exposures 
differently from controls because of their illness in case control studies (28).  
2.1.3 Low fiber intake: 
Dietary fibers are polysaccharides that escape digestion in the small intestine. 
They are further classified according to their solubility, plant source and degree of 
bacterial fermentation upon reaching the colon (29). 
Fiber intake was thought to protect against CRC through speeding up transit, 
increasing stool bulk, thereby diluting the carcinogens present in the gut lumen and 
reducing exposure to toxins and adsorption of bile acids (30-32). Several studies 
conducted found the evidence for dietary fiber to be inconsistent. This could be in part 
due to dietary measurement methods, source, and chemical composition of the fiber 
(10;33;33;34). 
A study conducted comparing the intake of starch, non-starch polysaccharides and 
fat among 12 populations worldwide found a strong inverse relationship between starch 
consumption and large bowel cancer (RR= 0.7) (35). Another theory proposed that starch 
that escapes digestion and absorption in the small intestine undergoes fermentation by 
colonic bacteria and thus produces short chain fatty acids such as butyrate which may 
have a role in reducing the malignant changes of colonic epithelial cells.  This was partly 
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supported by a recent in vitro study that found butyrate and carnitine to inhibit human 
colon carcinoma cell proliferation and induce apoptosis in human colon carcinoma cells 
(36). 
This attracted more attention to the role of gut flora in producing short chain fatty 
acids through fermentation and their essential role in maintaining large intestinal health. 
These findings caused Bolin TD to raise the question whether subclinical malabsorption 
of CHO (carbohydrates) in Asia and Africa that leads to an increased CHO load and 
fermentation in the large intestine is the reason behind the lower incidence of CRC 
compared to western countries (37). 
 
2.1.4 Phytoestrogen Intake 
Lignan and isoflavones are dietary phytoestrogens found in plant foods. Lignans 
are found in flaxseed, grains, nuts, fruits, and vegetables and isoflavones are found in soy 
products. A case-control study of the relationship between dietary intakes of lignans and 
risk of colorectal cancer showed that there was a significant reduction in colorectal 
cancer risk when comparing the highest intakes of lignan to the lowest = 0.71; 95% CI, 
0.56 – 0.94, p value for trend = 0.01) (2). 
 
It is thought that phytoestrogens may act via: 1) hormonal effects mediated by ER 
(estrogen receptor) binding; 2) non-hormonal actions by altering processes involved in 
carcinogenesis such as apoptosis and antioxidant activity; or 3) interaction with enzymes 
involved in sex steroid biosynthesis and metabolism (38-40) . Isoflavones may alter 
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CYP(1A1,1A2,1B1)-mediated estradiol metabolism by reducing formation of 
carcinogenic hydroxylated metabolites  while increasing less reactive 2-OH estrone and 
16α-OH estrone metabolites (41). Also, phytoestrogens may inhibit CYP-dependent 
estrogen metabolism by acting as competitive substrates, or they may reduce circulating 
levels of estradiol by induction of CYP enzymes (2). 
 
2.1.5 Meat consumption and colorectal cancer 
Several studies showed that processed meat intake may be involved in the 
etiology of CRC with an estimated RR ~ 2 which is modest compared to RR of lung 
cancer due to cigarette smoking (relative risk (RR=20) (42-44).   
Many carcinogens resulting from meat processing were suggested, the most likely 
being N-nitroso compounds (NOC) promoted by heme in the meat. This was supported 
by an associated increase in NOC-specific alkylating DNA adducts in colonic epithelial 
cells following by consumption of high meat diet (45;46). Other carcinogens such as 
Heterocyclic amines (HCA) and Polycyclic aromatic hydrocarbons (PCA) could be 
involved (47), however they are not specific for processed meat as they are found in 
significant amounts in chicken (48). Based on epidemiologic studies, risk for CRC was 
not significant for chicken meat consumption (49) . 
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2.1.5.1 Possible mechanisms relating red meat to CRC development: 
Meat consumption is the major source of dietary arginine in humans, with high 
quantities of arginine found not only in red meat but also in pork, fish and chicken. 
Importantly, arginine is the key substrate for two competing metabolic pathways believed 
to be involved in carcinogenesis: the nitric oxide (NO) synthase pathway and polyamine 
synthesis. First, Arginine is catabolized by NO synthase 2 (NOS2) and other NO 
synthases to form nitric oxide. Inducible isoforms of NOS2 are abundant in human 
colorectal adenomas (50). All isoforms of NOS require five cofactors/prosthetic groups 
such as flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), heme, BH4 
and Ca2+-calmodulin. If NOS lacks its substrate, L-arginine or one of its cofactors, NOS 
may produce •O2- instead of •NO and this is referred to as the uncoupled state of NOS 
(51-54). 
Second, Arginine is catabolized by the enzyme arginase to form ornithine, the 
substrate for putrescine synthesis. This is the first step in polyamine biosynthesis and is 
catalyzed by the enzyme ornithine decarboxylase (ODC) (55). Multiple abnormalities in 
the control of polyamine content results in increased polyamine levels that can promote 
tumorigenesis (56).  
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Figure (1) Arginine synthesis, metabolism and catabolism. Alternate pathways and 
inhibitors of these pathways are indicated. NOS, nitric oxide synthase; DFMO, 
difluoromethylornithine; ODC, ornithine decarboxylase; NSAIDs, non-steroidal anti-
inflammatory drugs; SSAT, spermidine/spermine N1-acetyltransferase; OAT, ornithine 
aminotransferase; HCAs, heterocyclic amines; PAHs, polycyclic aromatic hydrocarbons; 
NOCs, N-nitroso compounds (57). 
 
Also, raw red meat contains high levels of oxymyoglobin and oxyhemoglobin on 
the surface of muscle, deoxymyoglobin and deoxyhemoglobin in the interior of muscle, 
and cytochromes of mitochondria in muscle and other tissues. The concentration of red 
color of the meat indicates the amount of mitochondria as well as the concentration of the 
major heme pigments. In cooked red meat, myoglobins, hemoglobins and cytochromes 
are converted into denatured protein-hemes, the hemichromes and hemochromes. After 
being eaten, heme proteins are hydrolyzed to amino acids and peptides and the heme 
group which is coordinated with strong ligands. The iron of heme coordinates to the 
sulfur, nitrogen or oxygen of amino acids and peptides and other biological components. 
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The coordinated heme groups are absorbed and transported by the blood to every organ 
and tissue (58). Free and coordinated heme preferentially catalyzes oxidative reactions 
such as lipid peroxidation. Heme catalyzed oxidations can damage lipids, proteins, DNA 
and other nucleic acids and various components of biological systems.  Heme catalysis of 
oxidation is the strongest oxidizing system for developing tissue damage. These heme-
catalyzed oxidations can lead to the initiation of biochemical and cellular damage and 
subsequently to disease processes (59) . 
Evidence that heme from consumed red meat travels down the GI tract comes 
from studies of the occult blood test. The occult blood test detects hemoglobin and heme 
in stools from bleeding in the GI tract. That the occult blood test can give a false positive 
if a large amount of red meat is consumed shows that heme has been transferred through 
the GI tract (59). 
 
2.1.6 Micronutrients and colorectal cancer:  
2.1.6.1 Ca and vit D:  
 Calcium has been evaluated for its potential protective effect. Increased Ca intake 
is associated with decreased risk of colorectal cancer in epidemiological studies. Calcium 
has been associated with increasing cellular differentiation and apoptosis in both normal 
and tumor cells. For colorectal cancer, Ca may bind bile and fatty acids in the intestinal 
tract and thereby keep these compounds from damaging the intestinal mucosa (60).  
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Two intervention and six prospective studies provided information about the 
relationship between supplemental calcium intake and colorectal cancer reduction (61). 
One intervention study reported a significant reduction, however modest (RR=0.81), in 
recurrent colorectal polyps after supplementation with 1.2 g/day of Ca (62). The other 
intervention study recruited fewer subjects and thus was less powered. It reported 
reduced risk however not significant of colorectal cancer following calcium 
supplementation (63). Of the six prospectively designed observational studies, four 
reported some type of significant association (RR ranged from 0.76 - 0.6) between 
calcium supplements and the risk reduction of colorectal cancer, whereas two studies 
reported no association. Again, the studies that have reported protective associations for 
supplemental calcium were the cohorts with the largest number of subjects that contained 
both genders and a broad age range of subjects (64-69).  
On the other hand, most epidemiological studies have reported that higher serum 
25-hydroxyvitamin D levels are associated with lower incidence rates of various cancers 
(70-72). Almost all laboratory studies using tissue culture systems have reported 
inhibition of growth of malignant cells and many have identified re-differentiation in 
response to vitamin D metabolites especially 1, 25 (OH)2D3(73-78).  
A profound inverse association of serum 25(OH)D with age standardized 
colorectal cancer mortality  was found in the National Health and Nutrition Examination 
Survey III (NHANES) cohort. Individuals with serum 25(OH)D greater than 32 ng/ml 
had approximately one fourth the risk of dying of colon cancer as those with poor vitamin 
D status (<20 ng/ml) (RR= 0.28) (79).  
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The proposed molecular action of 1,25(OH)2D3 on growth of colon cancer cells 
was demonstrated first by the finding that not only renal, but also cells from the heart, 
stomach, pancreas, colon, brain, skin, gonads and others have the nuclear receptor for 
1,25(OH)2D3, the so called vitamin D receptor (VDR), and such tissues are potential 
targets for 1,25(OH)2D3 activity. Many of these VDR-positive tissues are known to be 
targets for development of sporadic malignancies (80). Bound to its receptor, 
1,25(OH)2D3 controls growth of normal and neoplastic cells and also controls cellular 
proliferation, differentiation and apoptosis (81-83). The relevance of VDR activation by 
1,25(OH)2D3  was investigated experimentally by using mice which were genetically 
altered to block 1,25(OH)2D3/VDR signaling. The colon mucosa of VDR-null mice 
shows a pattern of increased DNA damage and cell division (84;85).  
            Dietary intake of vitamin D3 typically supplies only 10-20% of the daily 
requirement, whereas up to 80-90% comes from UV-B mediated synthesis of vitamin D3 
in the epidermis (this depends on latitude and the season).  
The preventive effects of higher vitD3 intake have led 16 vitamin D scientists in the 
United States and Canada to disseminate a call to action recommending universal daily 
intake of 2000 IU of vitamin D3 (72).  
To maximize the efficiency of vitamin D in reducing the risk of colorectal cancer, 
it has been hypothesized that an optimal level of calcium has to be reached first. This was 
supported by a clinical trial of supplemental calcium (1400-1500 mg) with or without 
vitamin D3 (1100 IU) for lowering fracture risk in 1179 women. A statistically 
significant reduction in all cancer incidence (a secondary endpoint) occurred in the 
calcium plus vitamin D arm (OR=0.4) and a marginally significant reduction occurred in 
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the calcium alone arm. Another study found that 25(OH)D3 levels were associated with a 
reduced risk of adenoma recurrence only among subjects with high calcium intake (86).    
The synergistic effect of calcium and vitamin D was not supported by a well-
organized double-blinded clinical trial where patients were randomized to receive 
calcium carbonate (2000 mg/d) and / or vitamin D (800 IU/day) or placebo. They found 
that in normal colon mucosa, the apoptosis markers increased by a statistically significant 
56% among individuals treated with vitamin D only. And these apoptosis markers 
increased by a statistically non-significant 33% in patients receiving calcium or calcium 
plus vitamin D. It was proposed that the combination of calcium and vitamin D was not 
as effective as vitamin D alone in promoting apoptosis. And possibly calcium did not add 
but also blunted the apoptotic effects of vitamin D (87). Apparently more research is 
needed to examine the molecular and the biological action of calcium and vitamin D on 
colon mucosa cells.  
   
2.1.6.2 Folate and other one-carbon metabolism biomarkers 
One-carbon metabolism reactions encompass a group of biological processes with 
two major functions: synthesis of purines and pyrimidines needed for DNA replication 
and repair and synthesis of S-adenosyl methionine, a methyl group donor for a number of 
methylation reactions including DNA methylation. 5-Methyl tetrahydrofolate provides 
the folate substrate for the remethylation conversion of homocysteine to methionine, the 
precursor to S-adenosylmethionine, and vitamin B12 serves as a cofactor for the reaction. 
The resulting tetrahydrofolate is converted to 5,10-methylene tetrahydrofolate in a 
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reaction requiring vitamin B2 Riboflavin, as flavin adenine dinucleotide, is the cofactor 
for methylenetetrahydrofolate reductase (MTHFR), the enzyme that influences 
homocysteine remethylation and DNA methylation. In a separate transsulfuration 
pathway, homocysteine is metabolized to cysteine via vitamin B6-dependent enzymes 
(88-90).  
Low concentrations of these one-carbon related serum nutrients (i.e., folate, 
vitamun B6, vitamin B12, and riboflavin) may lead to elevated homocysteine, disrupted 
one-carbon metabolism, and insufficient methyl groups for DNA methylation, synthesis, 
or repair, thus potentially promoting carcinogenesis (89;91). 
           Experimental and human-based studies have linked folate to decreased colon 
cancer risk. Although some of these data suggest that folate and other one carbon markers 
should be protective, there is also evidence that folate's roles in cell signaling, may 
contribute to carcinogenesis. As folate is critical to cellular repair, folate-deficient or even 
depleted patients could well be at increased risk. On the contrary, a key mechanism of 
some chemotherapeutic agents is folate depletion. Epidemiologic evidence has tended to 
link folate to decreased risk. Nonetheless, clinical trials of folate supplementation have in 
general not confirmed these results. A recent clinical trial reported that supplementation 
with 1mg/day folic acid did not reduce but may have increased the recurrence of multiple 
and advanced colorectal adenomas (92;93). These results generated a hypothesis that 
folic acid might act in a bimodal way; deficiency may increase the risk of mutation, thus 
of tumerogenesis, but that supplementation may increase the survival and replication of 
mutated cells (94).  
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          Similarly, studies investigating the role of vitamin B6 in colorectal cancer 
development are inconsistent, a recent meta-analysis concluded that dietary vitamin B6 
intake and supplementation is inversely associated with colorectal cancer (95). However, 
a recent population-based prospective cohort design with a long follow-up period found 
that vitamin B6 is associated with increased risk of rectal cancer especially among 
women (91;96). The inconsistencies could be attributed to measurement error of food 
frequency questionnaire and non adjustment of unknown confounders (97). 
2.1.6.3 B-carotene  
Retinol (vitamin A1) and its metabolites are essential in a wide range of 
physiological regulatory processes. At the molecular and cellular level, this regulation 
involves the control of cell proliferation and differentiation through retinoid-dependent 
effects on gene expression.  
Epidemiologic studies, and laboratory experiments have suggested that carotenoids may 
control cell growth and may also play a role in carcinogenesis. Many studies observed 
strong associations between intakes of B-carotene rich foods and reduced risk of 
colorectal cancer. However, interest in B-carotene as a chemopreventive agent declined 
markedly as double blind, randomized clinical trials of B-carotene among average to high 
risk populations indicated that B-carotene probably increases the risk of some cancers 
and has no impact on the risk of several others (98). Results from recent intervention 
studies, the Beta-Carotene and Retinol Efficacy Trial [CARET] and the Alpha-
Tocopherol, ß-Carotene Cancer Prevention Study [ATBC], indicated that exposure of 
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subjects taking supplemental ß-carotene to cigarette smoke increased lung cancer 
incidence (99). 
 
2.2 Lifestyle Factors 
2.2.1 Alcohol consumption and colorectal cancer 
The risk of colorectal cancer was significantly associated with alcohol: 
individuals consuming the most alcohol had 60% greater risk of colorectal cancer 
compared with non- or light drinkers (relative risk 1.56, 95% CI 1.42-1.70)(6). 
2.2.1.1 Mechanisms relating Alcohol to CRC development: 
Although alcohol itself is not carcinogenic, alcohol's first metabolite, 
acetaldehyde, is emerging as an important mal-factor, being able to form stable DNA 
adducts, trigger mutations in tumor suppressors and oncogenes, and to interfere with 
DNA repair (100). 
The pathological effects of alcohol consumption on the colorectal tract have been 
extensively investigated but still remain largely unclear. Evidence exists for the 
involvement of acetaldehyde (101), but also other mechanisms have been linked to CRC, 
e.g. the induction of reactive oxygen species through the induction of cytochrome P-450 
2E (102-104). Other molecular changes seen in CRC involve alterations in DNA 
methylation, e.g. induction of expression of oncogenes and silencing of tumour 
suppressor genes (105). Many of the above-described processes have been observed in 
heavy or chronic alcohol consumers. The amount of damage related to alcohol tends to 
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follow a dose–response relationship and, as such, (very) high levels of daily alcohol 
intake may be needed for genetic mutations to occur.  
   
2.2.2 Physical activity: 
There is compelling evidence linking physical inactivity and obesity with an 
increased risk of developing colon cancer. A recent meta-analysis was conducted. The 
meta-analysis included only longitudinal observations where current weight, height and 
leisure time exercise were assessed before the diagnosis of cancer and did not rely on 
retrospective recall of past habits. They show that higher levels of leisure time-physical 
activity are associated with modest reductions (14-20%) in risk of colon cancer in men 
and women with a dose response relationship, but no apparent reductions in risk of rectal 
cancer in either men or women (106). This is in general agreement with other studies; 
however, the magnitude of risk reduction may differ (107-110). This meta-analysis also 
showed that the protective effect of physical activity decreased after adjustment for BMI 
especially in men (RR before BMI adjustment= 0.58, RR after BMI adjustment=0.80) 
(106). If obesity is considered as a marker of prolonged excess of energy intake, this 
suggests that physical activity and BMI are not independent from each other. 
          Several hypotheses provide an interpretation for the obesity- cancer relationship. 
The hyperinsulinemia hypothesis states that chronic elevated insulin promotes the 
proliferation of colonic cells including cancerous clones. The effect can be direct or 
indirect by increasing circulating levels of free insulin-like growth factors. The same 
mechanism could explain the protective effect of physical activity which reduces 
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circulating levels of insulin. This was supported experimentally in animal studies (111). 
  To explore the effect of calories on carcinogenesis in greater detail, several animal 
studies confirmed the inhibitory effect of caloric restriction on tumorigenesis. One study 
examined the effect of 40% restriction of calories in rats, where absolute saturated fat 
intake was increased. Interestingly, this study demonstrates that the tumor-reducing effect 
of calorie restriction dominates even if the fat intake increases during calorie restriction. 
Thus total energy is an important determinant in colon carcinogenesis. Whether caloric 
restriction is achieved by dietary means or through increased consumption by exercise, 
whichever is more efficient, needs to be further investigated in human studies (112). 
 
2.2.3 Smoking and Colorectal cancer; 
Several studies have linked cigarette smoking and alcohol intake to many cancers. 
The association of cigarette smoking and colon cancer is much smaller than that between 
smoking and lung cancer. Nonetheless, the impact of tobacco smoking on colon cancer 
risk is evident. A meta-analysis of prospective cohort studies show that current male 
smokers carry 38% increased risk of colorectal cancer than non smokers.. 
 
2.2.4 Obesity and colorectal cancer 
The pooled estimate indicated that individuals with a BMI ≥30 kg/m2 had a 40% 
greater risk of colorectal cancer compared with individuals with a BMI ≤25 kg/m2(6). 
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2.2.4.1 Positive energy balance (PEB) and obesity in relation to CRC: 
Excess weight has been associated with increased mortality from all cancers 
combined and for cancers of several specific sites. Overweight and obesity are clinically 
defined indicators of a disease process characterized by the accumulation of body fat due 
to an excess of energy intake (nutritional intake) relative to energy expenditure (physical 
activity). When energy intake exceeds energy expenditure over a prolonged period of 
time, the result is a positive energy balance (PEB), which leads to the development of 
obesity. This physical state is ideal for intervention and can be modulated by changes in 
energy intake, expenditure, or both (113).  
The outcome of PEB, excess adipose tissue, has two main categories: 
subcutaneous and visceral. Subcutaneous adipose is defined as fat tissue between the skin 
and muscle, whereas visceral adipose tissue is found within the main cavities of the body, 
primarily in the abdominal cavity. Abdominal visceral adipocytes are more metabolically 
active and linked to a series of reactions leading to carcinogenesis (114). 
 Several measures are used to define obesity. The most utilized parameter is body 
mass index (BMI) (weight in kilograms divided by height in meters squared), a measure 
of overall overweight status. The World Health Organization (WHO) defined an 
overweight status as a BMI of 25.0 or higher. Only two techniques can distinguish 
between subcutaneous and visceral fat abdominal adipose tissue. They are computed 
tomography (CT) and magnetic resonance imaging (MRI). These two techniques are too 
costly and complex to be used in large-scale epidemiologic studies. Therefore, the waist-
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to hip ratio (WHR), the circumference of the waist and hip, is used as a proxy measure of 
central adiposity (115). 
Studies in animals showed that restriction of calories by 10 to 40% has been shown to 
decrease cell proliferation, increasing apoptosis through anti angiogenic processes(115). 
 
2.2.4.2 Mechanisms Relating Positive Energy Balance to Cancer Risk 
Many studies have tried to explain the mechanisms which link obesity with 
colorectal cancer, among them are: Insulin resistance, chronic inflammation, and the 
adiponectin theory. 
 
Insulin resistance and CRC development. The term insulin resistance refers to a 
state of cellular unresponsiveness to the effects of insulin with higher levels of insulin 
required to normalize plasma glucose. Insulin resistance is believed to underlie a cluster 
of metabolic abnormalities including elevated levels of blood triglycerides and glucose, 
low levels of high-density lipoprotein cholesterol and high blood pressure (116).  
 
At least three mechanisms exist through which insulin resistance potentially 
causes colorectal cancer (116). The elevated concentrations of plasma insulin, 
triglycerides, NEFA and glucose associated with insulin resistance lead to increased 
insulin exposure of non-classical insulin target tissues that express insulin receptors, such 
as the colon. This can potentially have a number of consequences. First, insulin is known 
to have growth as well as metabolic effects. Specifically, insulin stimulates proliferation 
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and reduces apoptosis in colorectal cancer cell lines (117;118), and it promotes colorectal 
tumor growth in animal models (119-121). Because the colon is not a classical insulin-
target tissue, the colonocyte may lack a specific mechanism through which the mitogenic 
actions of insulin are regulated, as is the case in classical insulin target tissues such as 
skeletal muscle, adipose tissue and liver. Thus, elevated insulin signaling in the 
colonocyte may engender an enhanced proliferative state with tumorigenic consequences 
(122). 
Second, in conjunction with the metabolic effects of insulin, the increased 
concentrations of available energy substrates such as glucose, triglycerides and NEFA 
may provide increased energy for transformed colonocytes as well as induce changes in 
cell signaling pathways. Elevated intracellular levels of triglycerides and their 
metabolites such as diacylglycerol may activate the protein kinase-C and MAPK 
pathways with potentially mitogenic and carcinogenic effects (123). Triglycerides and 
other fat metabolites are known to affect the activity of peroxisome proliferator activated 
receptors (PPARs), a class of transcription factors that play key roles in lipid, glucose and 
energy homeostasis and in adipocyte differentiation regulation. PPARs have 
antiproliferative, proapoptotic and anti-inflammatory effects (124). Peroxisome 
proliferator-activated receptor gamma (PPAR-g) is expressed in colonic tissue and 
inhibits the growth and increases the differentiation of colonic tumors (125).  
Increased energy availability may also contribute to colon carcinogenesis by stimulating 
reactive oxygen species synthesis. An intracellular lipolytic environment rich in 
oxidizable substrates may result in the generation of lipid oxidation products, depleted 
levels of antioxidants and an overall environment of oxidative stress (126). 
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Hyperglycemia may also increase oxidative stress (127). In support of this, DNA damage 
is known to be higher in diabetic individuals compared with healthy subjects (128). 
Third, insulin resistance causes alterations in the IGF system with concomitant 
effects on cellular growth pathways. Insulin and IGF are representative of energy 
availability and stimulate anabolic pathways, leading to cell growth and differentiation. 
In the hyperinsulinemic state, IGF-binding protein (IGFBP) levels decrease, whereas free 
IGF-1 levels rise (129). The colon expresses IGF receptors, and following activation by 
IGF binding, colonocyte apoptosis is inhibited and cell cycle progression ensues. 
Elevated levels of IGF may therefore provide a selective growth stimulus, causing clonal 
expansion of epithelial cells with abnormal growth regulation. High circulating levels of 
IGF-1 have been positively associated with colorectal cancer risk, whereas high IGFBP-3 
levels are associated with reduced risk (130;131). Furthermore, sufferers of acromegaly, a 
condition characterized by overproduction of  IGF and growth hormone (GH), have 
increased risk of developing colorectal cancer (132). 
 
Inflammation. Overweight and obese individuals experience low-grade systemic 
inflammation. IL-6 is secreted by visceral adipose tissue, in vivo, particularly in obese 
individuals. Long-term secretion of IL-6 dampens the production of Tumor Necrosis 
Factor-? (TNF-?) and stimulates C-Reactive Protein (CRP) (133). 
A recent cohort study conducted in older adults aged 70 – 79 years found that elevated 
baseline levels of IL-6, CRP, and TNF-? were associated with an increased risk of 
cancer events. Colorectal cancer risk was associated with IL-6 and CRP, which is 
consistent with findings from another nested case-control study (134;135) .  
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Adiponectin.  Adipose tissue, which is the largest endocrine organ in the body, 
plays an important role in regulating energy metabolism and inflammation, and has also 
been associated with several cancers. Adiponectin, a 30-kDa complement C1-related 
protein, is the most abundant gene product secreted by fat cells (136)  and is a key 
regulator of insulin sensitivity (137;138)  and inflammation (139;140). Adiponectin 
modulates several physiologic processes, such as metabolism of glucose and fatty acids 
(141), and decreased plasma adiponectin concentrations are associated with insulin 
resistance, type 2 diabetes (142), and atherosclerosis (143). In addition, it has recently 
been shown that adiponectin may play a role in the development and progression of 
various types of malignancies(144). 
            A large, prospective, nested case-control study found that plasma adiponectin 
concentrations were inversely associated with risk of colorectal cancer in men (145) . 
Men with the highest concentrations had  ~60% reduced risk for colorectal cancer 
compared with those with the lowest concentrations, even after adjustment for body size, 
waist circumference, and physical activity (145). In addition, it was found that colorectal 
tumors express adiponectin receptors, and that this expression is significantly higher than 
in non-tumorous colorectal tissue from colorectal cancer patients. The elevated 
expression of AdipoR1 and AdipoR2 further indicate a potential role of adiponectin in 
the pathogenesis of colorectal cancer (144). 
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2.2.5 Cigarette smoking and colorectal cancer 
In a meta-analysis of prospective cohort studies, the risk of CRC among male 
smokers (RR, 1.38; 95% CI, 1.22-1.56) was more significant than among female smokers 
(RR, 1.06; 95% CI, 0.95-1.19). Former smokers still carried a higher CRC risk than 
subjects who never smoked. The increased risk of CRC was related to cigarettes per day, 
longer years of smoking, or larger pack-years (146). 
 
2.2.6 Antiinflammatory drugs and CRC 
Much data indicate that long-term users of aspirin and nonsteroidal anti-
inflammatory drugs (NSAIDs) reduces colon cancer risk by 40–50%, The ability of 
NSAIDs to inhibit cyclo-oxygenases (COX-1 and -2) underlies their mechanism(s) of 
chemoprevention (147). COX-2 converts arachidonic acid to prostaglandins, which in 
turn induce inflammatory reactions in damaged tissues. Aspirin irreversibly inactivates 
both COX-1 and COX-2. Inactivation prevents platelet synthesis of prostaglandins, 
endoperoxides and thromboxane A2 (148).  
2.3 Previous Medical Interventions 
2.3.1 Pelvic Irradiation 
Previous exposure to pelvic radiation may be associated with a higher risk of 
CRC after a 5- to 10-year lag period (149). A history of radiation therapy for prostate 
cancer correlated with an increased risk of rectal cancer in a large retrospective study 
(150). 
  
28 
 
2.3.2 Ureterocolic Anastomosis 
A few studies have reported an apparently increased risk of colorectal neoplasia 
near ureterocolic anastomoses after major surgery of the urinary or intestinal tract 
(151;152). The presumed mechanism is exposure of colonic mucosa to carcinogenic 
substances from the urinary system. 
 
2.4 Concurrent Medical Conditions 
2.4.1 Inflammatory Bowel Disease (IBD) 
Inflammatory bowel diseases include at least two forms of intestinal 
inflammation: Ulcerative colitis and Crohn’s disease, the causes of which are unknown. 
Ulcerative colitis and Crohn’s disease are distinguished by their typical clinical, 
pathologic, radiologic, endoscopic, and laboratory features (153). 
Patients with chronic IBD involving the colon are at significantly increased risk for CRC 
(154;155).  In ulcerative colitis (UC), the risk of CRC depends on the duration and extent 
of disease. The risk is highest in those with extensive colitis or “ pancolitis, ” with a 
standardized incidence ratio of 2.4 according to a population-based study in the USA 
(156). 
            More recent studies have reported that the risk of CRC in long-standing Crohn’s 
disease (CD) involving the colon is probably comparable to that of UC (157-160). CRC 
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in CD develops over a similar time frame as in UC (161;162). The mean age of onset for 
IBD-associated CRC is lower than that for sporadic CRC (45 versus 60 years). 
Although inflammatory mechanisms have been associated with the development 
of colon cancer that arises either sporadically (135;163;164), or with IBD, the link to 
inflammation is stronger in IBD-associated carcinogenesis (165). 
By comparing the different mechanisms leading to colon cancer, the role of inflammation 
in carcinogenesis has been investigated. In both sporadic and IBD-associated colon 
cancer, carcinogenesis is associated with genetic instability arising from both 
chromosomal instability and microsatellite instability. However, the clinical features of 
these two types of colon cancer differ(165). In sporadic cancer, a progression from 
adenoma to carcinoma is apparent, with the dysplastic precursor generally localized to a 
discrete focus. In contrast, IBD-associated carcinogenesis results when the epithelium in 
areas of inflammation progresses to dysplasia and then to carcinoma, with dysplastic 
lesions generally appearing as multifocal and diffuse. In addition, the timing and 
frequencies of molecular alterations in sporadic and IBD associated colon cancer differ 
(165). Molecular alterations that contribute to the development of sporadic colon cancer 
include the loss of chromosomal material (loss of heterozygosity), microsatellite 
instability, and aberrant DNA methylation. In IBD-associated colon cancer, these 
mechanisms are also implicated but they generally occur simultaneously and early in the 
progression to carcinogenesis. The early occurrence of these three common factors 
suggests inflammation plays a causative role (166).  
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2.4.1.1 Mechanisms relating Chronic Inflammation to CRC: 
The gastrointestinal tract is continuously exposed to various environmental 
antigens, including not only the beneficial microbes residing there, but also a wide 
variety of toxins and pathogens (167). Therefore, it is important that an efficient immune 
system is present along the entire length of the gut. 
Tissue inflammation such as gastritis, esophagitis, and hepatitis, which are caused 
not only by chronic infection but also by physical and chemical agents such as heat, acid, 
UV, tobacco smoke, and foreign bodies (e.g., asbestos), are also recognized risk factors 
for human cancer at various sites. In addition, autoimmune and inflammatory reactions of 
uncertain etiology (e.g., pernicious anemia, ulcerative colitis, pancreatitis, etc.) are 
associated with increased risk of cancer.  
The mechanisms of carcinogenesis associated with infection and inflammation 
have not been fully elucidated. Three main mechanisms have been proposed to account 
for infection-associated carcinogenesis: First, direct action of the infectious agent on host 
cells or tissues which leads to alterations of host DNA (insertion, deletion, translocation, 
and amplification). Tumor-suppressor gene products such as pRB and p53 are also 
inactivated by interaction with products of integrated viral DNA (e.g., the X-protein of 
hepatitis B virus, the E6 and E7 proteins of human papillomavirus) .Second, viral 
infection (e.g., with human immunodeficiency virus) may cause immunosuppression, 
which can enhance some types of malignancy (e.g., Kaposi’s sarcoma). And third, it was 
found that prolonged activation of inflammatory cells generates ROS and RNS that can 
damage host DNA and tissues and contribute to carcinogenesis (168). 
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Production of ROS and RNS in inflammation induced cancer. Infection and 
inflammation activate a variety of inflammatory cells, which induce and activate various 
oxidant-generating enzymes . These include NADPH oxidase and xanthine oxidase, 
which produce superoxide anion (O●¯2), inducible nitric oxide synthase (iNOS), which 
produces nitric oxide (NO●) from L-arginine, and myeloperoxidase (MPO), which 
generates hypochlorous acid (HOCl) using hydrogen peroxide (H2O2) and chloride ion 
(Cl‾) as substrates. Peroxidases such as MPO  can also catalytically generate nitrogen 
dioxide (NO● 2) using H2O2 and nitrite as substrates (169;170). 
Under normal conditions, free radicals have a role in body defense mechanism against 
bacteria and viruses (171). 
Free radicals may react with phospholipids of membranes generating hydroperoxides, 
lipoperoxides and toxic aldehydes such as malondialdehyde (MDA), which in turn may 
alter membrane permeability and microcirculation. ROI, RNI and their derivative 
products may also activate nuclear factors such as, for example, NF-KB, leading to the 
production of other proinflammatory cytokines, which in turn enhance inflammation and, 
therefore, the generation of more reactive species (172). The imbalance in redox status 
and the enhanced production of intermediate reactive species progressively consumes the 
antioxidant defenses, leading the cells to develop oxidative stress. Cells could respond to 
these insults by enhancing their antioxidant potential or by activating the system of 
caspases that induce programmed cell death (apoptosis). It is also possible that oxidative 
stress induces cell necrosis through the release of cytochrome c and the depletion of ATP 
at the mitochondrial level (173;174). Peroxynitrite participates with the apoptotic 
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program through the nitrosylation of proteins, which in turn alters the function of several 
signaling molecules including NF-KB, p53 and caspases (175-177). When the system 
fails in one or more than one step, the possibility of developing a mutated cell increases 
as a consequence of the high perturbation in the redox status that progresses, through ROI 
and RNI, into the nucleus (178). 
On the other hand, nitric oxide (NO) is generated specifically during 
inflammation via iNOS in inflammatory and epithelial cells. Excess NO production plays 
a crucial role in  cancer (168). NO reacts with superoxide (O●¯2) to form peroxynitrite 
(ONOO-), a highly reactive species causing nitrative and oxidative DNA damage. 
ONOO- can mediate the formation of 8-Oxo-2'-deoxyguanosine (8- oxodG) (179) and 8-
nitroguanine, a marker of nitrative DNA damage (180;181). 8-Nitroguanine is considered 
to be not only a marker of inflammation, but also a potential mutagenic DNA lesion 
product, leading to carcinogenesis (182). 
2.4.2 Diabetes Mellitus type 2 
DM is a group of metabolic disorders characterized by hyperglycemia. The two 
most frequent subtypes of diabetes mellitus differ for both metabolic and hormonal 
characteristics: in type 1 diabetic patients (5-10% of all diabetics) hyperglycemia is 
associated with an absolute deficiency of endogenous insulin secretion and the absolute 
requirement for exogenous insulin administration.  
In type 2 diabetes hyperglycemia and hyperinsulinemia coexist for a long time 
because of the insulin resistance of peripheral tissues. Only when the beta-cell function 
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fails completely, will the patient require insulin treatment because of endogenous insulin 
deficiency (183).  
            Type 2 diabetes has been associated with an increased risk of colorectal adenomas 
and carcinomas in most, but not all, studies. The risk is increased in both women and men 
for both colon and rectal cancer (184).  
            Hyperinsulinemia has been suggested as a link between CRC and diabetes as 
insulin is a growth factor not only with metabolic, but also mitogenic effects, and its 
action in malignant cells is favored by mechanisms acting both at the receptor and post-
receptor level cells (185;186). Chronic insulin therapy has been associated with an 
increased colorectal tumor risk among type 2 diabetic patients (187). Specifically, a 
three-fold risk increase for patients with insulin-dependent type 2 DM in comparison to 
the general population has been observed (188).  
In most type 2 diabetic patients hyperglycemia is associated with endogenous 
hyperinsulinemia, a compensatory state caused by insulin resistance. This condition often 
persists for many years. Therefore, in these patients, excess unused substrates (i.e. 
glucose) are present concomitantly with hyperinsulinemia. This abnormal situation is 
accompanied by a series of other abnormalities involving other hormones, like glucagon, 
incretins, leptin, etc.  
             As DM persists for many years, most type 2 diabetic patients progress from 
progressively decreased insulin secretion to failure of B-cells to secrete insulin.  
At this stage, patients with type 2 diabetes may become similar to type 1 diabetic 
individuals (189).  
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 If hyperinsulinemia has a role in promoting cancer initiation and/or progression, 
these aspects should be considered when determining the individual risk of a diabetic 
patient to develop cancer. Most studies on the diabetes-cancer association overlooked 
these different biological conditions. Therefore, it is inappropriate to consider diabetic 
patients as a homogenous cohort.  In conducting a new study, a number of confounders 
should be adjusted for first; endogenous insulin status, obesity, quality of metabolic 
control and drugs used for treatment (190). 
2.4.3 Human Immunodeficiency Virus Infection 
Some studies have shown an increase in the incidence of colorectal neoplasia in 
patients infected with the human immunodeficiency virus (191). This is thought to be a 
result of increased susceptibility to carcinogenesis due to chronic immunosuppression. 
 
2.4.4 Allergy: 
In a prospective study involving 21,292 Iowa women followed for 8 years allergy 
was defined from four self-reported questions about physician-diagnosed as asthma (a), 
hay fever (b), eczema or allergy of the skin (c), and other allergic conditions (d). It was 
found that history of any allergy was inversely associated with incident colorectal cancer: 
after multivariate adjustment, the hazard ratio (HR) was 0.74 [95% confidence interval 
(95% CI), 0.59-0.94] compared with women with no allergy (192). 
The observed inverse associations, if causal, may reflect enhanced 
immunosurveillance in allergic participants (i.e., the enhanced ability of the immune 
system to detect and eliminate cancer cells before they become clinically manifest). This 
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hypothesis is consistent with findings in other epidemiologic studies that showed 
decreased risk estimates for various cancers, such as pancreatic cancer, liver cancer, 
glioma, and breast cancer, associated with a history of allergy (193-198). The hypothesis 
that allergies lead to enhanced immunosurveillance is supported by laboratory studies 
that show that allergy is accompanied by immunoglobulin E production, a significant 
decrease in tumor occurrence and growth, and an increase in survival time in sensitized 
mice (199-201).  
2.4.5 Acromegaly 
A prospective controlled study found that adenomatous polyps occurred in 22% of male 
acromegalic patients compared with 8% of control subjects (202). Patients with 
acromegaly were more likely to have multiple and proximal adenomas. Reduced 
expression of the PPAR gene has been implicated in such patients (203). 
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3 Molecular basis of Colorectal cancer 
 
3.1 Introduction: 
Three major categories of genes have been implicated in carcinoma development:  
(1) oncogenes, (2) tumor suppressor genes, and (3) mismatch repair genes 
 
 
 
Table (1) Genes Known to Be Involved in Development of Colorectal Carcinoma (204). 
 
When a proto-oncogene (a normal human growth related gene) becomes 
abnormally activated, it drives the cell through the cell cycle facilitating clonal 
proliferation and is known as an oncogene. Oncogenes act in a dominant fashion because 
alteration of only one allele is necessary to produce a cellular effect. 
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Other genes called tumor suppressor genes can halt the cell cycle even when 
oncogenes are altered. Tumor suppressor genes act in a recessive manner and promote 
carcinoma only when they are inactivated by allelic loss or mutations in both alleles. If 
cells cannot repair DNA damage, tumor suppressor genes such as p53 drive the cell into a 
suicide mode called apoptosis. 
The latest genes found to be related to carcinogenesis are called mismatch repair 
genes, which are needed for cells to repair DNA replication errors and spontaneous base 
pair loss (204). 
 
3.2 Genes involved and Genetic pathways in colorectal cancer: 
There are two major genetic mechanisms responsible for colorectal 
carcinogenesis. Most likely there are other mechanisms yet undiscovered. First, the 
chromosomal instability (CIN) pathway, the accumulation of mutations in tumor-
suppressor genes and oncogenes, as well as other epigenetic changes such as hyper- or 
hypomethylation of DNA, that drive the cells to become malignant. This pathway is 
referred to as the suppressor pathway or chromosomal instability pathway.  Second, the 
mutator pathway in which inactivation of the mismatch repair genes leads to the 
accumulation of mutations (insertions or deletions) in microsatellites. These are DNA 
repetitive sequences located throughout the genome. These microsatellite mutations may 
lead to genomic instability, which, in turn, may accelerate further accumulation of 
mutations in other cancer genes during tumorigenesis(205).  
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The common theme of these pathways is genomic instability. The result of 
genomic instability is the accumulation of mutations that provide a survival advantage to 
specific clones of cells, which eventually could become carcinogenic. These mutations 
occur in genes that control cell growth and cell death (206). 
Tumors developing along the mutator pathway are characterized by microsatellite 
instability and, in general, are diploid, whereas tumors originating via CIN are usually 
aneuploid. 
 
3.2.1 Genes Involved in CIN 
Mutations in the APC gene are common in both pre-malignant and malignant 
colorectal neoplasms. Germ line mutations in the APC gene are characteristic of FAP 
(Familial Adenomatous Polyposis).  The APC gene is located in chromosome 5q21. It 
consists of 16 exons encoding a 2,861-amino-acid protein (207).  Somatic mutations in 
the APC gene occur in sporadic colorectal cancers, whereas in FAP, a germ line mutation 
is inherited and a somatic mutation acquired. As occurs in FAP, in sporadic colorectal 
cancer, the second mutation depends on the site of the first mutation (208). Depending on 
the location of the first hit, the second hit may be an allelic loss or another truncating 
mutation (209). 
K-ras is a proto-oncogene involved in signal transduction (210). Oncogenic 
mutations in k-ras allow k-ras to remain activated and to interact with downstream 
signaling molecules to stimulate cell proliferation. Even though k-ras mutations have 
been identified in aberrant crypt foci, they are rarely seen in adenomas smaller than 1 cm 
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(211). They are common in larger adenomas and in colorectal carcinomas, which 
suggests that k-ras mutations occur later in the pathogenesis of colorectal cancer (212). 
The TP53 gene is located in chromosome 17p. The p53 protein is a transcription 
factor with tumor-suppressor properties (210). Activated p53 will result in transcription 
of genes that regulate cell-cycle progression, apoptosis, and inhibition of angiogenesis by 
induction of thrombospodin-1 (TSP1) (213).  
The deletion in colon cancer (DCC) gene is located in chromosome 18q. 
Mutations in DCC are more frequent as adenomas progress to carcinomas. (212).  
3.3 Genetic Pathways:  
The concept of multi-step ‘adenoma–carcinoma’ sequence involving the 
inactivation of APC (the ‘gatekeeper’) and the subsequent stepwise mutation of several 
other genes such as K-ras and p53 have been proposed in the past decades (214).  
One critical observation is the finding that nearly 70% of sporadic (average-risk) 
colorectal adenomatous polyps harbor somatic APC mutations (215).  
3.3.1 Loss of Heterozygosity :  
APC gene inactivation leads to a pathway termed loss of heterozygosity (LOH). 
Approximately 70% to 80% of colorectal carcinoma develops through the LOH pathway 
following inactivation of the APC gene. The genes involved in the LOH pathway include 
K-ras, DCC, and p53 in addition to APC. Germline APC mutations initiate the neoplastic 
process in patients with familial adenomatous polyposis (FAP) and endow all colonic 
crypt stem cells with a high risk for clonal proliferation. 
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The cascade of events begins with a loss or mutation of the APC gene on 
chromosome 5q, resulting in a change from normal epithelium to hyperproliferative 
epithelium. One of these hyperproliferating cells gives rise to a small adenoma in which 
the genome is hypomethylated. The next event involves activation of the K-ras oncogene 
on the chromosome 12p mutation to form the intermediate adenoma. Unlike oncogenes, 
tumor suppressor genes are expressed in a recessive manner. Therefore, both allelic 
copies must be lost or inactivated by point mutations for phenotypic expression to occur. 
Usually the DCC gene on chromosome 18q is next to be deactivated or lost, and results in 
the development of a late adenoma. The final genetic alteration found consistently in 
colorectal carcinoma is loss and/or mutation of the p53 tumor suppressor gene on 
chromosome 17p. While there is no obligatory sequence of mutations in the pathway 
from normal mucosa through adenoma to carcinoma, there is clearly an association of 
certain types of mutations in specific oncogenes or tumor suppressor genes with early and 
late states of transformation. 
This multistep pathway can be observed both in sporadic and inherited colorectal 
carcinoma. Many other genes, such as MCC, TGF-b, and Myc, have been implicated in 
the genesis of colorectal carcinoma (212). 
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Figure (2) Progression of colorectal tumors with CIN. The hallmark of the CIN 
pathway is aneuploidy. Initiation of neoplasia in this pathway occurs by a somatic 
mutation in one allele and loss of heterozygosity of the second normal allele of the APC 
gene. Progression is then driven by successive waves of cellular clonal expansion that 
acquire enhanced growth characteristics and include mutational activation of the proto-
oncogene KRAS and mutation of TP53 with subsequent loss of heterozygosity of the 
normal remaining TP53 allele to allow carcinoma formation (210). 
3.3.2 Mutator Pathway, MSI (Microsatelite Instability): 
Colorectal tumors that develop through this pathway are initiated by inherited 
(HNPCC) or somatic mutations within one of the DNA mismatch repair genes namely, 
hMSH2, hMSH3, hMSH6, hMLH1, hPMS1, and hPMS2. Epigenetic silencing of the 
hMLH1 promoter is another mechanism of inactivating hMLH1(4). Colorectal tumors 
generated via the mutator pathway are characterized by microsatellite instability. MSI has 
been defined as microsatellite instability-high (MSI-H), microsatellite instability-low 
(MSI-L), and microsatellite stable (MSS), depending on the number of unstable loci 
(216). 
 Microsatellite instability is involved in the genesis of about 15% of sporadic 
CRCs and most of hereditary non-polyposis CRCs (HNPCC) (217;218). The multiple 
errors in repetitive DNA sequences (microsatellites) result from a failure of the DNA 
mismatch repair (MMR) system to edit errors made during DNA replication. The DNA 
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MMR system is inactivated either by hypermethylation of the promoter, which silences 
gene transcription of hMLH1 (epigenetic phenomenon; sporadic CRC), or because of 
germ-like mutations in MMR genes MLH1, MSH2, MSH6 and others (genetic 
phenomenon, HNPCC) (4). 
Mismatch repair gene defects initiate an entirely different sequence of events 
known as the replication error (RER) pathway. These pathways lead to carcinomas that 
are biologically quite different. This second pathway to colorectal carcinoma is found in 
approximately 20% of carcinomas.  
 Patients with HNPCC inherit a single defective allele of a mismatch repair gene 
and require an additional somatic mutation to inactivate the second allele. Spontaneous 
carcinomas develop after two somatic events inactivate the relevant gene. In either case, 
inactivation leads to a marked increase in replication errors. As errors accumulate in 
microsatellites, malfunction of genes that contain or are near affected microsatellites may 
occur. RER-positive phenotype was found in 77% of colorectal carcinomas from HNPCC 
patients compared with only 13% of patients with sporadic carcinoma (219). 
Each pathway appears to prevail in a different colorectal area, and to be 
associated with a different histotype and prognosis: the CIN pathway in tumors of the 
left/distal colon, which are usually aneuploid , highly differentiated, rarely mucinous, 
with no lymphocyte infiltration; the MSI pathway in tumors of the right/proximal colon, 
which are diploid, poorly differentiated, often mucinous, with Crohn-like lymphocyte 
infiltrate (220). 
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Figure (3) Progression of colorectal tumors with MSI. MSI tumors, whether sporadic 
or from patients with Lynch syndrome, lose MMR function early in the polyp → cancer 
progression sequence. Sporadic tumors almost uniformly lose MMR function due to 
hypermethylation of the promoter of hMLH1, whereas patients with Lynch syndrome 
have a germline mutation in one of the MMR genes (210). 
3.3.3 Epigenetic alterations and Epigenetic instability: 
Epigenetics (from the Greek “upon” genetics) is a modification of the genome, as 
opposed to being part of the genome.  
The diversity in cancer cell populations is believed to be due to: (a) accumulation of 
genetic changes (e.g., mutations) that lead to differential gene expression, thereby 
allowing for uncontrollable cell growth, and (b) epigenetic (stable) heritable changes in 
gene expression mechanisms (not attributable to nucleotide sequence variation) that 
describe the interactions of genes with the environment. Most CRCs have two main 
epigenetic abnormalities: DNA methylation and core histone modifications, which 
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coexist with more classical genetic changes such as p53, k-ras and β-catenin mutations. 
These epigenetic effects have an important role in development, but can also arise as 
individuals age (221). 
DNA is wrapped around a core of eight histones to form nucleosomes (the 
smallest structure unit of the chromatin) that function as DNA packaging units and as 
transcriptional regulators. The amino terminal tail of histones protrudes out from the 
nucleosome and are subject to posttranslational chemical modifications such as 
phosphorylation, ADP-ribosylation, glycosylation, biotinylation, acetylation by histone 
acetyltransferases (HATs), and methylation by histone lysine methyltransferases (HMTs). 
Unlike histone lysine acetylation, histone lysine methylation can result in either 
activation or repression, depending on the residue on which it resides; in this way, 
specific modifications of histone tail residues can be used as markers of transcriptionally 
active or inactive chromatin (222). Histone modifications affect the access of regulatory 
factors and complexes to chromatin, thereby influencing gene expression (223). 
 Aberrant methylation of DNA (global hypomethylation of promoter regions of 
genes accompanied by region-specific hypermethylations) is frequently found in tumor 
cells. Global hypomethylation leading to overexpression of oncogenes can result in 
chromosomal instability (CIN) present in >50% of colorectal cancers (CRCs) (224). 
Methylation occurs via the covalent addition of a methyl group to the 5- position of the 
cytosine ring within the context of a cytosine nucleotide followed by a guanine 
nucleotide (CpG dinucleotide). The term CpG island methylation phenotype (CIMP+) 
was introduced several years ago to describe tumors that display frequent and concurrent 
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hypermethylation of multiple CpG islands in new and known genes, including the 
mismatch repair gene human Mut L homolog 1 (hMLH) (225) . 
Hypermethylation also occurs in the aging process and these acquired changes 
may dispose elderly individuals to neoplasia. For example, an increase in methylation of 
the estrogen receptor (ER) gene in normal colonic tissue, as well as in highly methylated 
colon tumors, as a function of age was reported.  Age-related methylation and subsequent 
inactivation of tumor suppressor genes have been suggested as a predisposing factor for 
the increased risk of cancer with age (226). 
 
3.4 Clinical syndromes: 
The APC and mismatch repair genes were found to initiate FAP and HNPCC, the 
two main autosomal dominantly inherited CRC’s, respectively (227). More recently, 
different initiating genes have been found for other familiar CRC syndromes (228).  
3.4.1 Inherited syndromes: 
3.4.1.1 Lynch syndrome or HNPCC 
The most common form of hereditary CRC is Lynch Syndrome  (LS), also known 
as hereditary non-polyposis colorectal cancer (HNPCC), which accounts for 2–5% of the 
total CRC burden (229). 
Heterozygous germ-line mutations in the DNA MMR genes MSH2 and MLH1 are 
responsible for most HNPCC families, while MSH6 and PMS2 are less frequently 
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involved (230). Tumors arise as a result of somatic inactivation of the same MMR gene 
that is mutated in the germline. 
The name LS is used for families with a verified MMR gene mutation. Families 
with clinical features of LS but no molecular genetic verification are known as HNPCC. 
 
3.4.1.2 Familial adenomatous polyposis coli (FAP) 
FAP is the most common polyposis syndrome, with a frequency varying from 1 in 
10 000 to 1 in 30 000 persons. The genetic defect in FAP is a germ-line mutation in the 
APC gene. FAP is characterized by the occurrence of  >100 polyps (adenomas) in the 
colon and rectum, although the number of polyps is often much higher and they usually 
become visible at before age twenty. The life-long risk for CRC is practically 100% and 
the average age of onset of CRC is 40 years without prophylactic colectomy (231). FAP 
patients also have a risk of other tumors. Diffuse mesenteric fibromatosis, termed 
desmoid tumor, occurs in 20–30% of patients, often after colectomy and this benign 
tumor may cause premature death due to abdominal and retroperitoneal complications 
related to the growth of the desmoid (232). FAP patients may also have duodenal 
adenomas which sometimes show malignant transformation and therefore upper-
gastrointestinal endoscopy is included in the surveillance protocol (231). Other rare 
tumors associated with FAP are hepatoblastoma, thyroid cancer, brain tumors (Turcot 
syndrome) and gastric and pancreatic cancer. 
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3.4.1.3 Juvenile polyposis (JP) and Peutz–Jeghers syndrome (PJS) 
Juvenile polyposis (JP) and Peutz–Jeghers syndrome (PJS) are two other 
gastrointestinal-polyposis syndromes predisposing to CRC. They are rare (1 in 100 000) 
and can be diagnosed on the basis of special histological features of the polyps 
(hamartomas). Germ-line mutation in the LKB1 gene predisposes for PJS and mutations 
in two different genes (SMAD4 or BMPR1A) for JP (233). 
 
3.4.1.4 MUTYH-associated adenomatous polyposis (MAP) 
A subset (about 15%) of APC mutation-negative patients with no autosomal 
dominant inheritance display adenomatous polyps ranging from 15 to 100 (234).  
The MYH gene on human chromosome 1p33-34 is a base excision repair gene in which 
germline mutations have been found in association with multiple colorectal adenomatous 
polyps (235). These mutations may be missense or nonsense, the latter yielding protein 
truncation (236). 
 
3.4.2 Familial CRC: 
Ten to fifteen percent of patients with colorectal carcinoma and/or colorectal 
adenomas have other affected family members but their family histories do not fit the 
criteria for either FAP or HNPCC and may not appear to follow a recognizable pattern of 
inheritance, such as autosomal dominant inheritance. Such families are categorized as 
having familial colorectal carcinoma. The presence of colorectal carcinoma in more than 
  
48 
one family member may be due to genetic factors, shared environmental risk factors or 
even to chance (237). 
A positive family history of CRC increases the estimated risk for CRC by two to 
four-fold. This means that life-long risk of CRC is between 10% and 20% in persons with 
a positive family history if they are living in a country with a high incidence of CRC. The 
enrichment of low penetrance susceptibility genes has been suggested as an explanation 
for the increased risk, but very little evidence has been obtained as yet (233).   
3.4.3 Sporadic CRC 
Approximately 75% of all new cases of colorectal carcinoma occur in people with 
no known predisposing factors for the disease. Incidence increases with age, beginning 
around 40 years (238). People with no predisposing factors are considered to be at 
average risk for colorectal carcinoma.  
CRC develops through different pathways. The common mechanism (more than 
50% of sporadic CRCs) is that of chromosomal instability (CIN) (239-241). The second 
pathway (35% of sporadic CRCs) is caused by epigenetic inactivation of tumor 
suppressor genes. Because of the mechanism involved in this, it is called the CpG island 
methylator phenotype (CIMP). A third pathway is caused by failure of the DNA 
mismatch repair system, and these tumors have a characteristic signature mutation called 
microsatellite instability (MSI), MSI-high (MSI-H), MSI-low (MSI-L) or MSI-stable 
(MSS) (242).  
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4 Screening methods for Colorectal Cancer: 
The goal of colorectal cancer screening is to identify early cancers and 
adenomatous polyps by mass screening of all average-risk adults 50 years and older 
(243). 
An average-risk adult is defined as an asymptomatic person without a personal or family 
history of adenomatous polyps or other illness (e.g., IBD, FAP, HNPCC) that predisposes 
to colorectal cancer. Persons at increased risk require more intensive screening(244). 
 
Canadian Task Force on Preventive Health Care, 2001 (245)	  •	  Good	  evidence	  to	  support	  annual	  or	  biennial	  fecal	  occult	  blood	  test	  (FOBT).	  •	  Fair	  evidence	  to	  include	  flexible	  sigmoidoscopy	  in	  the	  periodic	  health	  examination	  of	  patients	  aged	  50	  years	  or	  older.	  	  •	  Insufficient	  evidence	  to	  include	  or	  exclude	  colonoscopy	  as	  an	  initial	  screening	  test.	  	  
National Committee on Colorectal Cancer Screening, 2002(246)	  •	  Recommends	  biennial	  (at	  minimum)	  FOBT	  for	  average-­‐risk	  people	  aged	  50	  to	  74.	  •	  Recommends	  follow-­‐up	  of	  positive	  FOBT	  by	  colonoscopy.	  •	  Recommends	  screening	  occur	  in	  organized	  provincial	  programs,	  with	  ongoing	  evaluation.	  
Table (2) Screening Guidelines for Canadians at Average Risk for Colorectal Cancer 
 
In Canada, guidelines for colorectal cancer screening recommend an FOBT every 
two years for people aged 50–74 who are at average risk for the disease. It is 
estimated that if 80% of Canadians within this age range had a biennial FOBT with 
appropriate follow-up through organized screening, alongside any opportunistic 
testing that occurs outside of organized programs, 10,000 to 15,000 colorectal cancer 
  
50 
deaths could be avoided over the next 10 years (247;248). 
The National Colorectal Cancer Screening Network was launched by the Canadian 
Partnership Against Cancer in late 2007 to support the development of evidence-based 
screening programs and policy. As of the fall 2010, several organized colorectal cancer 
screening programs were established across Canada, with eight provinces currently 
running full or pilot programs and two provinces having announced intentions for a 
program. Each program follows the recommendations for colorectal cancer 
screening set out in the population-based guidelines developed in 2002. All 
programs are using some variation of the FOBT as the entry test—either the guaiac 
fecal occult blood test (gFOBT) or the fecal immunochemical test (FIT). 
 
4.1 Structural examinations 
4.1.1  Flexible sigmoidoscopy (FSIG) 
The examination uses a sigmoidoscope, a flexible, lighted tube about the 
thickness of a finger with a small video camera at the end, so the images are displayed on 
a monitor. As the sigmoidoscope is only 60 cm long, it can see the entire rectum but less 
than half of the colon with the procedure. In addition, the examination can be done with 
different endoscopic instruments, such as a colonoscopy, an upper endoscope, and a 
pediatric colonoscopy. The main advantage of FSIG is that it can be performed with a 
simple preparation (2 Fleet enemas). However, bowel cleansing is best achieved through 
an oral sodium phosphate procedure. Patients had a more favourable experience with the 
oral preparation than with enemas (249). The examination usually lasts 10-20 min. The 
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absence of sedation is perceived by some patients as a benefit and by others as a 
disadvantage. Often, patients undergoing sigmoidoscopy relate more discomfort than 
patients undergoing colonoscopy. Moreover, the lack of sedation is related to greater 
reluctance of patients to undergo an examination for future screening. 
4.1.2 Colonoscopy 
The examination assesses the entire length of the colon and rectum with a 
colonoscope, which is basically a longer version of a sigmoidoscope. The colonoscope 
has a camera on the end that is connected to a monitor so we can see and closely examine 
the inside of the colon. The modern colonoscope can examine the entire intestine, with 
the examination terminating in a cecum. Patients typically take a liquid diet one or more 
days before the examination, followed by oral ingestion of lavender or saline laxatives to 
stimulate intestinal movements until the intestine is clean. Proper bowel preparation is a 
critical element in accuracy and cost-effectiveness of screening with colonoscopy (250). 
It is common for patients to receive a mild sedative before the procedure, but it is not 
essential for those who tolerate the procedure with only mild discomfort(251). 
The test usually takes about 30 min, although it may take longer if a polyp is 
found and removed. The examination allows direct mucosal inspection of the entire colon 
and possibly a biopsy sample or even a definitive treatment such as polypectomy. The 
colonoscope is lubricated so that it can be easily inserted into the rectum. Once in the 
rectum, the colonoscope goes through the transverse colon and ascending colon. The 
colonoscope will deliver air into the colon so that it is easier to see the lining of the colon 
and to use the tools to perform the test. If a small polyp is found, it can be removed. This 
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is done by a wire running through the circuit colonoscope to cut the polyp from the wall 
of the colon with an electric current. In the case of a large polyp, cancer or anything else 
abnormal, a biopsy can be done. For this procedure, a small piece of tissue is taken by the 
colonoscope. Moreover, the tissue must be examined under a microscope to determine 
whether it is a cancer, a benign (not cancerous) growth, or a result of inflammation (252). 
 
4.1.3 CT colonography 
CT colonography is an imaging-only examination and does not offer the 
therapeutic option of polypectomy that optical colonoscopy does; however, in several 
current CT colonography screening programs, same-day colonoscopy after a positive CT 
colonographic study is being offered to eliminate a second bowel preparation for the 
patient (253). 
CT colonography offers several advantages compared with other colorectal 
screening methods; it also has known limitations and risks. Advantages of CT 
colonography include that it is a minimally invasive, whole-colon structural examination 
with high sensitivity for detection of advanced neoplasia. The test is time efficient, 
typically taking 10 minutes at CT, which includes placement of a rectal tube with bowel 
insufflation. No sedation, recovery time, or need for a scheduled driver after the 
procedure is required, and patients have the capability to return to work the same day 
(254). 
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4.2 Stool-based markers  
4.2.1 1-Fecal Occult Blood Testing  
Fecal occult blood testing (FOBT) is the most widely used screening test for 
CRC. Two main types of FOBT exist, the guaiac test (g-FOBT), which is based on the 
peroxidase like activity of haem in haemoglobin, and the immunochemical test (i-FOBT), 
which detects the globin moiety in haemoglobin. Of these two, the guaiac test has been 
the more widely evaluated. It is a non-invasive simple test that requires no patient 
preparation but has a low sensitivity for CRC detection (40 - 85%). Four randomized 
trials have shown that screening with the guaiac based FOBT reduced both the incidence 
by approximately 20% and mortality of CRC by about 16% (255).  
A study comparing i-FOBT to g-FOBT and colonoscopy as a gold standard found 
that for invasive cancers, sensitivity of i-FOBT is one and a half times more than g-FOBT 
and, sensitivity of i-FOBT is 3.3 times higher than g-FOBT for high risk adenomas. This 
demonstrates that i-FOBT outperforms g-FOBT and the increase in sensitivity for the 
detection of high risk adenomas is significantly greater than that of invasive cancers 
which makes it suitable for detection of patients at earlier stages (256).               
   
4.2.2  Fecal DNA-based tests  
Fecal DNA tests detect mutant or abnormal DNA shed from neoplastic colorectal 
lesions that is excreted in the stool. Since no single gene has been identified that is altered 
in all CRCs, a panel of DNA markers is usually employed. The most frequently measured 
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markers in stool include mutant K-ras, mutant APC, mutant P 53, BAT-26 and long DNA 
(257).  
Studies show that DNA marker panels have a specificity of 95% or greater. 
However, sensitivity varied from 60% to 90%. To compare the use of specific DNA 
panels to FOBT, a large population based study was conducted. DNA panel detected 16 
out of 31 invasive cancers, whereas FOBT detected only four. Of the 71 invasive cancers 
and adenomas diagnosed with high-grade dysplasia, the DNA panel detected 29 while 
FOBT detected only ten. In subjects with negative findings on colonoscopy, the DNA 
panel had a specificity of 94.4% and FOBT had a specificity of 95.2%. Although neither 
techniques detected the majority of neoplastic lesions, the DNA panel displayed a higher 
sensitivity than FOBT without reduced specificity (258-260).  
Despite the better performance of the DNA panel as compared with FOBT, its 
overall low sensitivity in asymptomatic subjects, coupled with relatively high cost and 
assay complexity makes it unlikely that molecular markers will replace the FOBT as a 
widely used screening tests for CRC. 
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5  Diagnosis and treatment of CRC 
Prognostic markers are defined as markers which can identify patients with 
differing risks of a specific outcome, such as tumor progression or death but are not used 
to guide the choice of a particular therapy. A predictive marker is one that predicts the 
differential efficacy or benefit of a particular therapy based on marker status and 
therefore could be used to guide the choice of therapy (261). 
5.1 Tumor node metastasis (TNM) staging:  
TNM stage remains the gold standard of prognostic factors in CRC. The TNM 
staging was initially developed to predict prognosis, but its function has expanded to aid 
in the choice of treatment and in the selection of patients for clinical trials. 
 The stage often takes into account the size of a tumor, how deeply it has penetrated, 
whether it has invaded adjacent organs, how many lymph nodes it has metastasized to (if 
any), and whether it has spread to distant organs (262).  
TNM Staging System (Tumor, Node, Metastasis)  
Tumor  
T1: Tumor invades submucosa.  
T2: Tumor invades muscularis propria.  
T3: Tumor invades through the muscularis propria into the subserosa, or into the 
pericolic or perirectal tissues.  
T4: Tumor directly invades other organs or structures, and/or perforates.  
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Node  
N0: No regional lymph node metastasis.  
N1: Metastasis in one to three regional lymph nodes.  
N2: Metastasis in four or more regional lymph nodes.  
Metastasis  
M0: No distant metastasis.  
M1: Distant metastasis present.  
Stage Groupings  
Stage I: T1 N0 M0; T2 N0 M0  
Cancer has begun to spread, but is still in the inner lining.  
Stage II: T3 N0 M0; T4 N0 M0  
Cancer has spread to other organs near the colon or rectum. It has not reached lymph 
nodes.  
Stage III: any T, N1-2, M0  
Cancer has spread to lymph nodes, but has not been carried to distant parts of the body.  
Stage IV: any T, any N, M1  
Cancer has been carried through the lymph system to distant parts of the body. This is 
known as metastasis. The most likely organs to experience metastasis from colorectal 
cancer are the lungs and liver.  
Most colorectal cancer patients present with symptoms such as bleeding, 
obstruction or abdominal pain, although increasing numbers of cases are identified 
through screening. The diagnosis of colorectal cancer is commonly made using 
colonoscopy or sigmoidoscopy, which enables physicians to identify the exact location of 
the tumour and perform a biopsy. A barium enema and computed tomography (CT) 
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scanning may also be used. Following diagnosis, staging tests such as CT scans are 
frequently performed. 
The treatment of stage I, II and III colorectal carcinoma typically involves surgery: _	  For some stage II and for stage III colon cancer, chemotherapy after surgery is 
frequently used. _	  For stage II and stage III rectal cancer, a combination of chemotherapy and 
radiation is often provided, preferably before surgery. _	  Stage IV colorectal cancer, where there is spread to sites away from the primary 
tumour, is typically treated with palliative chemotherapy with surgery and/or 
radiation used predominately for symptoms. A small proportion of people with 
stage IV colorectal cancer can have long-term survival with aggressive surgery and 
chemotherapy (263). 
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6 Tumor markers 
6.1 Definition and clinical use 
Most researchers in this field prefer defining tumor markers as: a molecule, a 
process, or a substance that is altered quantitatively or qualitatively in precancerous or 
cancerous conditions, the alteration being detectable by an assay. Alterations can be 
produced either by the tumor itself or by the surrounding normal tissue as a response to 
tumor cells. The tumor marker itself can be DNA, mRNA, protein, or processes 
(apoptosis, angiogenesis, proliferation and so on) measured quantitatively or qualitatively 
by an appropriate assay (264). 
There are many possible clinical uses of tumor markers and several categories 
have been defined. A diagnostic tumor marker is a marker that will aid in detection of 
malignant disease in an individual, if the marker is to be used for mass screening; a 
fundamental prerequisite is to exhibit both high levels of diagnostic sensitivity and 
specificity (265). Meanwhile, a prognostic marker gives the clinician a tool for 
estimating the risk of disease recurrence and/or cancer-related death for an individual 
patient following the initial surgical removal of the cancer but without administration of 
adjuvant therapy. In contrast, a predictive tumor marker will predict how the patient is 
going to respond to a given therapy (266). Many markers may have both a prognostic and 
a predictive value, an example of this is the Estrogen receptor (ER) content on breast 
tumours which plays two important roles: First, ER is a prognostic marker, in that ER-
negative tumours are associated with greater failure hazard; and second, ER is a 
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predictive marker for response to anti-estrogen drugs. Virtually no response is noted in 
patients with ER-negative tumours, while those with ER-positive tumours respond (267). 
 
6.2 Quality Requirements for the Use of Tumour Markers in Clinical 
practice: 
Diagnostic test accuracy refers to the ability of a test to discriminate between 
those who have and those who do not have the target condition. Accuracy is assessed by 
the results of the index test, the test under evaluation, with the results of the reference 
standard, which aims to classify patients as having or not having the target condition. The 
aim of diagnostic test evaluation is to address clinical questions such as "Should the 
patient undergo this diagnostic test?" and after ordering the test and seeing the test result, 
"What is the likelihood that this patient has the disease.  
   
   
6.2.1 Defining Diagnostic Test Accuracy  
6.2.1.1 Sensitivity and Specificity  
Sensitivity is the probability of a positive test result (that is, the test indicates the 
presence of disease) for a patient with the disease. Specificity, on the other hand, is the 
probability of a negative test result for a patient without the disease(that is, the test does 
not indicate the presence of disease).   
True-positives (TPs) are those patients with the disease who test positive. True-negatives 
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(TNs) are those without the disease who test negative. False-negatives (FNs) are those 
with the disease but the test falsely indicates the disease is not present. False-positives 
(FPs) are those without the disease but the test falsely indicates the presence of disease. 
Sensitivity, then is the probability of a TP among patients with the disease (TPs + FNs). 
Specificity, is the probability of a TN among patients without the disease (TNs + FPs).  
   
6.2.1.2 Positive and Negative Predictive Value:  
In clinical practice it is essential to know how a particular test result predicts the 
risk of abnormality. Sensitivities and specificities do not do this: they describe how 
abnormality (or normality) predicts particular test results. Predictive values do give 
probabilities of abnormality for particular test results, but depend on the prevalence of 
abnormality in the study sample and can rarely be generalized beyond the study (except 
when the study is based on a suitable random sample, as is sometimes the case for 
population screening studies) (268).  
An important question for the clinician to decide on the proper management for 
patients is "What is the likelihood that this patient has the disease when the test result is 
positive?" and "What is the likelihood that this patient does not have the disease when the 
test result is negative?"  
The positive predictive value (PPV) is the probability that the subject has the disease 
when the test is positive.  
PPV=TP/ (TP + FP) (269).  
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The PPV differs from sensitivity. While the PPV tells us the probability of a 
subject having the disease following a positive test (e.g., the probability of a subject 
having colorectal cancer after testing positive with GTA-446), the sensitivity tells us the 
probability that the test will be positive among subjects with the disease (e.g., the 
probability of testing positive for GTA-446 among colorectal cancer patients). PPV helps 
the clinicians decide how to treat the patient after the diagnostic test comes back positive. 
Sensitivity on the other hand is a feature of the diagnostic test and helps the clinician 
decide which test to use.  
The Negative Predictive Value (NPV) is the probability that the disease will not 
be present when the test is negative.  
NPV=TN/(TN + FN) (270) 
The NPV is different from the test's specificity. Specificity tells us the probability that the 
test will be negative among subjects without the disease (270) (e.g., the probability of 
negative GTA-446 test among subjects without colorectal cancer).  
   
6.2.1.3 Likelihood ratio:  
Each test result has its own likelihood ratio, which summarizes how many times 
more (or less) likely patients with the disease are to have that particular result than 
patients without the disease. More formally, it is the ratio of the probability of the 
specific test result in people who do have the disease to the probability in people who do 
not(271).  
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A likelihood ratio greater than 1 indicates that the test result is associated with the 
presence of the disease, whereas a likelihood ratio less than 1 indicates that the test result 
is associated with the absence of disease. The further likelihood ratios are from 1, the 
stronger the evidence for the presence or absence of disease. Likelihood ratios above 10 
and below 0.1 are considered to provide strong evidence to rule in or rule out diagnoses 
respectively in most circumstances. When tests report results as being either positive or 
negative the two likelihood ratios are called the positive likelihood ratio and the negative 
likelihood ratio.  
Positive Likelihood Ratio= Sensitivity / 1-Specificity  
Negative Likelihood Ratio= 1-Sensitivity / Specificity (272)  
 The likelihood ratio of a positive test result reflects the amount of certainty of 
having the disease that is gained after a positive test result, whereas the likelihood ratio of 
a negative test result is the amount of certainty gained of not having the disease with a 
negative test result(271).  
For example. A positive likelihood ratio of five is interpreted as 'in patients with the 
disease, a positive test is found five times as often as in patients without the disease.' The 
negative likelihood ratio on the other hand is the amount of information that is gained 
after a negative test result.  
A likelihood ratio close to 1 indicates that performing the test provides little 
additional information regarding the presence or absence of the disease. The likelihood 
ratios have the advantage of putting equal weights to the sensitivity and specificity and 
therefore being less dependent on the proportion of individuals under study who are 
diseased versus non-diseased (273).  
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6.2.1.4 Diagnostic Odds ratio (DOR)  
The DOR is equivalent to the ratio of positive and negative likelihood ratio  
DOR = Positive likelihood ratio / Negative likelihood ratio  
The value of a DOR ranges from 0 to infinity. A value of one means that a test does not 
discriminate between patients with the disorder and those without it.  
The advantage of the DOR is that it summarizes in one figure the diagnostic 
association between the test and the disease (274).  
An important notion is that odds ratios do not characterize the discriminatory 
capacity of a marker. The odds ratio is a simple scalar measure of association between 
marker and outcome. It does not characterize the discrimination between cases and 
controls that can be achieved by a marker since many different pairs of sensitivities and 
specificities are consistent with a particular odds ratio value (273;275). For example, for 
a marker with a sensitivity of 80% and specificity of 90%   the odds ratio is huge: 36. 
However, that even for an odds ratio as large as 36, one cannot conclude that the marker 
has good accuracy since a variety of (Sensitivity, Specificity) values are consistent with it 
(e.g., specificity = 0.50, sensitivity = 0.973) also yields an odds ratio of 36.  
    
6.2.1.5 Receiver operating characteristic curve (ROC);  
ROC is a plot of a test's false positive rate (FPR) or 1- specificity (plotted on the 
horizontal axis), versus its sensitivity (plotted in the vertical axis). Each point on the 
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curve represents the sensitivity and FPR at a different decision threshold. The plotted 
(FPR, sensitivity) coordinates are connected with line segments to construct an ROC 
curve. In an ROC curve, every possible decision threshold is considered (276).  
An ROC curve begins at the (0,0) coordinate, corresponding to the strictest 
decision threshold whereby all test results are negative for disease. The ROC curve ends 
at the (1, 1) coordinate, corresponding to the decision threshold whereby all test results 
are positive for disease. The line connecting the (0, 0) and (1, 1) coordinates is called the 
"chance diagonal" and represents the ROC curve of a diagnostic test with no ability to 
distinguish patients with versus those without disease. An ROC curve that lies above the 
chance diagonal has some diagnostic ability. The closer the ROC curve to the upper left 
hand corner, the better discriminating power and diagnostic accuracy the test has (277).  
The ROC curve of the test provides much more information about how the test 
performs than just a single estimate of the test's sensitivity and specificity. Given a test's 
ROC curve, a clinician can examine the trade-offs in sensitivity versus specificity for 
various decision thresholds. Based on the relative costs of false positive and false 
negative errors and pretest probability of disease, the clinician can choose the optimal 
decision threshold for each patient. One can derive the optimal cut-off from the relative 
importance of false positives and false negatives. For example, a missed (false negative) 
colorectal cancer is more serious than a false positive one (278).  
A measure of performance for the test is area under the ROC curve (AUC), it 
ranges in value from 0.5 (chance) to 1.0 (perfect discrimination or accuracy).  
AUC represents the probability that, when presented with a randomly chosen patient with 
disease and a randomly chosen patient without, the results of the diagnostic test will put 
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the patient with disease as having higher suspicion for disease than the patient without 
disease (279).  For example, if a biomarker has an AUC of 0.8 for differentiating between 
disease and non disease, this means, that if two subjects were randomly chosen from 
disease and non disease groups and the biomarker was measured and the test results are 
used to guess which of the two is the diseased, the test will be right 80% of the time.  
A key advantage for ROC is that ROC curve does not depend on how the marker 
is coded. Changing the units in which the marker is measured has no impact on its ROC.  
Moreover, ROC curves provide a natural common scale for comparing different markers 
even when they are measured in completely different units. In contrast, because odds 
ratios are interpreted per unit increase in the marker, odds ratios for two markers may not 
be comparable (278).  
6.2.1.6  Logistic regression for many diagnostic tests  
Logistic regression is a method for analysis of binary data, such as the presence or 
absence of disease.  
 
For a single dichotomous test the logistic regression equation is:  
  
where x stands for the test result and the coefficients have to be estimated.  
If a positive test result is coded as x = 1 and a negative as x = 0, we have  
  
which is the probability of having the disease given the test (x) is positive 
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and  
  
which is the probability of having the disease given the test (x) is negative. 
Next, diagnostic Odds Ratio is expressed as:  
 
In other words, the DOR equals the regression coefficient, after exponentiation (280).  
Logistic regression modeling has been proposed as the preferred statistical method to 
obtain a post-test probability of disease when results from multiple tests are available. 
History taking and physical examination can also be considered as individual diagnostic 
tests. The post test probability after having obtained test results xl,x2, ...xk is expressed as  
 (281) 
 With multiple dichotomous tests of which the results x1, x2 ... xk are coded as present 
(1) or absent (0), the corresponding coefficients B1, B2,…Bk equal the conditional 
logDOR. These DOR's are conditional: they depend on the other variables that have been 
used in the model. If more information becomes available a new regression equation has 
to be constructed to obtain the proper conditional DOR (280;282).  
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6.2.1.7 Confidence Intervals:  
It is important to assess how confident we can be about the test characteristics. If 
a test produces 80% sensitivity, it is unlikely that we will again find exactly 80% for 
sensitivity in a new series of patients, even when the same patients would have been 
retested in the same or another setting, different data will be obtained.  
The statistical method for analyzing the variability in estimates of diagnostic 
accuracy measurements is the use of confidence interval. The probability level of the 
confidence interval can be chosen (283).  
The interpretation of 95% confidence interval for an estimate is: when the data 
sampling is repeated many times, the 95% confidence interval calculated from each 
sample will, on average, contain the "true" value of the proportion in 95% of the samples 
(284).  
  
6.3 Problems introduced as a result of specific population selection  
The main objective to carry out a trial is to generalize the results beyond the study 
population itself. In order to do that, we need to know to what extent the patients we have 
studied are representative of all patients with the disease in question. 
In the design of any clinical diagnostic study, a fundamental requirement is to use a 
proper reference standard to which the diagnostic test is to be compared (285). 
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6.3.1 Referral bias:  
Referral bias occurs because people who are referred to participate in a study are 
often different from non-referrals (286). This could happen if a study is conducted in a 
large, specialized hospital that has a high concentration of rare, difficult or complex cases 
compared to real world population. The same effect could be obtained by physicians who 
voluntarily select these cases and refer them to participate in the study (285). 
Another source of referral bias is introduced when patients with a positive (or 
negative) diagnostic test are preferentially selected to receive verification by the "gold 
standard" examination. In the case of positive test results, the patients selected for 
additional workup are more likely to have disease than those excluded and therefore are 
more likely to have a true positive result. Alternatively, patients with negative results 
may actually have disease that goes undetected because definitive testing was not 
performed. These cases would normally increase the number of false negative reports, but 
because they are not identified they are erroneously labeled as true negatives (287).  
 
6.3.2 Population bias 
Population bias is introduced when there is a big difference in disease prevalence 
in the studied sample in comparison with what really exists in real population (288).  
A feature of PPV and NPV is their dependence on the prior probability of the disease 
(which is equal to the prevalence of disease in the population to be tested), i.e., if the 
disease prevalence increases, a positive test result will have a higher PPV. This is due to a 
relative decrease in the number of patients with a false-positive result to the number of 
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true positives. As a consequence, the proportion of true positives among the total number 
of those with a positive test result will rise, resulting in a higher PPV. The opposite will 
occur for NPV, that is higher disease prevalence will result in a lower NPV. Therefore, 
when comparing diagnostic accuracy measures between different populations, different 
results can be obtained. If the studied population has a high prevalence of the disease 
compared to the normal population, PPV will be erroneously overestimated and the 
assessment of the diagnostic test will be distorted (289). 
 
6.3.3 Spectrum bias  
When a diagnostic study starts by including patients who have already received a 
diagnosis of the target condition and uses a group of healthy volunteers as the control 
group, it is likely that both sensitivity and specificity will be higher than they would be in 
a study made up of patients only suspected of having the target condition. This feature 
has been described as spectrum bias (290). 
If the enrolled patients have disease type, severity, or duration that are clearly different 
from those of patients commonly found in clinical practice, a bias happens. 
In spectrum bias, mild cases that are difficult to diagnose are omitted from case-control 
studies, causing an overestimation of sensitivity as well as specificity (45). 
Indices of test efficacy, such as sensitivity, specificity, and likelihood ratios, are 
often considered to be fixed properties of a test that do not vary as disease prevalence 
changes among population (291).  However, different sensitivities and specificities could 
be obtained in women versus men, for elderly versus younger individuals and in patients 
with and without disease. For this reason, it is necessary to present strata-specific 
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estimates of the measures of disease accuracy for relevant subgroups. Also, the stage of 
disease severity could affect the sensitivity and specificity of a test.  
This shows that tests may perform differently in different groups of subjects and for 
different severities of disease (292). 
There are however particular situations where the study design purposefully 
includes spectrum bias. This is the case during the first attempts to evaluate the 
diagnostic performance for a given test. The first phase of evaluation of a new test is 
assessment of the test using a study including the “easily accessible population”. If the 
test performs badly here, it will certainly perform worse in clinical practice. Conversely, 
if the new test was found to have sufficient discriminative power, we can go ahead with 
other larger studies. However, even in the event of a very good performance of the new 
test in the first phase, we cannot transfer these results to clinical practice. The reason is 
the presence of a huge spectrum bias (293). 
After the initial experimental phase, if the purpose is to estimate the diagnostic 
performance of a new test to be applied in clinical practice, the solution of spectrum bias 
is to enroll a random sample of the population that could undergo the test modality in 
clinical practice. If the testing is for a screening method, a random sample of 
asymptomatic subjects with suitable demographics should be included (294). 
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7 HISTORY OF DISCOVERY OF GTA-446 
Phenomenome Discoveries Inc. (PDI) located in Saskatoon was able to detect a 
novel biomarker in the serum using a non-targeted approach. This approach characterizes 
the metabolic profiles to identify novel serum metabolomes in CRC patients compared to 
healthy controls. An advanced technology using high resolution Fourier Transform Ion 
Cyclotron Resonance Mass Spectrometry (FTICR-MS) was used to accurately identify 
the elemental composition of all ions detected in a sample. 
7.1 Patient samples used for the discovery project 
Three sets of samples were used in the discovery project, they were obtained from 
Genomics Collaborative Inc. (GCI), Seracare Life Sciences, and Osaka Medical 
Universities. GCI and Seracare were companies that specialize in the collection and 
storage of serum and tissue samples specifically for research purposes. 
 The total number of samples were 112 CRC patients and  matched controls. All 
samples were taken prior to any attempted treatment for CRC and were accompanied by 
detailed pathology reports. All samples were stored at -80◦c until time of analysis. 
7.2 Sample extraction protocol and technology used in discovery of the 
novel biomarkers 
Liquid extraction was performed on all serum samples by adding an equal volume 
of serum to 1% ammonium hydroxide in ethylacetate followed by centrifugation and 
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transfer of the top organic layer into a new tube. This process was repeated three times 
with pooling of the organic extract into a new tube (extract A). A one to five ratio of 
extract A to butanol was then evaporated under nitrogen to the original butanol starting 
volume which is now ready to be analyzed by FTICR-MS. 
7.2.1 FTICR-MS analysis 
Mass spectrometry is an analytical instrument that converts components of a 
sample into gaseous ions and measures their mass. This measurement is useful in the 
identification of compounds introduced into the mass spectrometer. Although there are 
many types and designs of mass spectrometers, there are common features among them. 
• All mass spectrometers ionize (charge) molecules (i.e. ion sources must be used to 
generate the gas-phase ions from a neutral sample) although the mechanisms for 
ionization vary markedly. 
• Every mass spectrometer has a mechanism to separate ions based on their mass (m) 
and the number of charges (z) present. This portion of the instrument is called the 
“mass analyzer” and can be of various designs and configurations. 
• All mass spectrometers have a detector that can detect the ions that reach it after 
having passed through the analyzer. 
Mass to charge ratio (m/z). An abbreviation used to denote the quantity formed 
by dividing the mass of an ion by the number of charges carried by it, e.g. a singly 
charged ion has an m/z equal to its mass. 
Nominal mass. This is the mass of  an ion calculated by adding the integer 
masses of the lightest isotopes of all elements contributing to a molecule. 
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Resolution. This is the ability of a mass spectrometer to distinguish between ions 
of different m/z  ratios. Greater resolution corresponds directly to the increased ability to 
differentiate ions of similar molecular weights (295). 
7.2.1.1 Principles of FTICR-MS 
Among all the different varieties of available mass spectrometers, FTICR-MS is 
considered a powerful instrument due to the inherently ultra-high resolution and mass 
accuracy which can be achieved. Separation of ions is based on their motion in a 
magnetic environment, which causes them to orbit at different frequencies, called 
cyclotron frequencies, depending on their m/z. Detection of the ions occurs as they pass 
two detector plates and generate an alternating electrical current . The magnitude of the 
signal is proportional to the total charge and the orbital radius (the proximity of the ions 
to the detection plates). The potential (voltage) change between the detection plates can 
be measured as a function of time. The frequency information is obtained from time-
domain data through a mathematical procedure known as “Fourier transform”. A second 
mathematical operation converts the frequency spectrum to a mass spectrum (296). 
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Figure (4) Simplified illustration of an FTICR-MS. Ions enter a circular path at 
different frequencies. These frequencies of rotation are detected and transformed 
mathematically into a mass value (295). 
7.2.1.2 Sample injection and data acquisition 
Extracted samples were directly injected at a flow rate of 600 uL/hour into 
FTICR-MS, and the instrument was calibrated such that each internal standard mass peak 
has a mass error of < 1 part per million compared with its theoretical mass. 
The compounds in the range of 100 -1000 m/z were analyzed and the mass 
spectra from each analysis were integrated and combined so as to create one data file per 
sample that contain all the unique masses. These data were then merged and extrapolated 
to create a two-dimensional metabolite array in which each sample is represented by 
column, and each unique metabolite is represented by a single row. 
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7.3 Results of data analysis  
Examination of the data showed an area of reduced peak intensities in the region 
of 440 and 600 Da in CRC patients relative to controls that was statistically significant. 
This was followed by ranking the top 50 masses based upon probability value from each 
of the three independent studies. Filtering for metabolic differences detected  in all three 
studies resulted in 13 masses that represent the most statistically significant and robust 
discriminators among the three studies. 
 Computational calculation of the molecular formulae were then carried out for 
the 13 masses to determine the number of carbons, hydorgens, oxygens, and other 
elements based on their exact mass. This resulted in the conclusion that the compounds 
are composed of either 28, 30, 32, or 36 carbons and four to six oxygen atoms. 
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Figure (5)Extracted mass spectrum of serum from normal subjects and colorectal 
cancer (CRC) patients. Extracts from five representative CRC and five control samples 
from the Genomics Collaborative discovery set were subject to high performance liquid 
chromatography followed by full-scan detection on an Applied Biosystems QSTAR 
XL™ mass spectrometer in atmospheric pressure chemical ionization negative mode. The 
average intensities of all ions within the mass range 100 to 700 Da eluting between 16 
and 18 min are shown for each cohort. The boxed region indicates spectral features 
present in normal patients but absent from CRC-positive serum (297). 
 
7.4 Structural elucidation 
Tandem mass spectrometry was used to identify the structure of the new 
molecules. Tandem mass spectrometry employs two series of mass analysis, the two steps 
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of mass analysis can be separated in either space (e.g. triple quadrupule) or time (e.g. ion 
traps). Most commonly, the first mass analyzer (MS1) isolates a single m/z value, called 
the “precursor ion”. Between MS1 and the second mass analyzer (MS2), ions are caused 
to dissociate into fragments, or “product ions” in a chamber called a “collision cell”. The 
fragmentation pattern of the precursor/product ion mass pair (called MS/MS transition) is 
exceptionally unique and highly selective, because two different ions (even with the same 
m/z) are unlikely to have the same precursor ion mass and product ion mass (295). 
 
Figure (6) Tandem MS illustrating all three quadrupole regions. The first is mass 
analyzer MS1; the second is the collision cell; and the third is the mass analyzer MS2, 
where the products of the collision cells are separated (295). 
 
 
  
78 
 
Figure (7) An illustration of the fragmentation of a generic molecule. The precursor 
ions fragment in a reproducible way, forming specific product ions. The product ions 
formed are based on the structure of the precursor ion (and thus the precursor molecules) 
(295). 
One of the common uses of the Tandem MS is chemical structure 
characterization. This helped shed some light on the structure of the novel biomarkers 
that were detected by FTICR-MS. Analysis of the Tandem mass spectrometric 
fragmentation fingerprints for the C28 molecules revealed main losses of H2O and CO2, 
indicating the presence of a carboxylic acid group and two or more hydroxyl groups. This 
prompted the hypothesis that these compounds could be derived from the same chemical 
family of fat soluble vitamins (Vitamins A, D, E, and K), steroids,  bile acids, or long 
chain polyunsaturated hydroxy fatty acids. Fragmentation patterns of standards of these 
compounds were compared against C28 molecules, none of them were similar to the C28 
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biomarker except for the hydroxyl fatty acid standards which showed peripheral and 
chain cut ions1 similar to those produced by MS/MS of the C28 molecules.  
7.5 Key clinical findings of the preliminary studies 
Three different sets of samples comprising three independent studies were used in 
the discovery project of the new biomarkers (GTA). All three studies showed a consistent 
reduction of these biomarkers among CRC patients compared to controls and ROC curve 
analysis resulted in an average area under-the-curve (AUC) of 0.91±0.03 across all three 
studies combined. 
In addition, the authors did not observe differences between genders in terms of 
GTA biomarker levels in the blood, neither did they observe any correlation between the 
reduction of metabolites and disease stage. Next, the level of the GTA markers were 
measured in 990 serum samples collected at SDCL along with age and gender data, 
results showed reduction of the level of these markers with increasing age (297). 
Finally, a study following up patients before and after colorectal cancer treatment 
revealed no restoration of the reduced level of GTA biomarkers post-treatment. 
                                                
1 This terminology is specific to fatty acid fragmentation.  MS/MS ions are clustered into three types: 
“peripheral-cut” ions, formed by neutral loss of water, CO2, amino acid, or amines derived from functional 
groups linking to the LM carbon chain as hydroxy, hydroperoxy, carbonyl, epoxy, carboxy, amino acid 
group, or amino group; “chain-cut” ions, formed by the cleavage of a carbon-carbon bond along the LM 
carbon chain; and “chain-plus-peripheral-cut” ions, formed by a combination of chain cut and peripheral 
cut. Molecular ions formed during ESI can easily be converted to peripheral-cut ions in the MS/MS 
process. Similarly, chain-cut ions can also be readily converted to chain-plus-peripheral-cut ions (298). 
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Treatment groups included those who had surgery, those who did not have surgery, and 
patients that did have surgery who subsequently had chemotherapy, or combination of 
chemo/radiotherapy. The authors concluded that these metabolites are not “tumour-
derived markers” and that the reduction is not likely the result of tumour burden. 
7.6 The proposed role of the new GTA biomarkers 
Structural elucidation of the new biomarkers showed them to be chemically 
related to long chain hydroxylated fatty acids. This directed the attention towards other 
known hydroxylated long chain fatty acids such as the resolvins and protectins that have 
a role in the resolution of acute inflammation (299). 
A hypothesis was generated that the new GTA biomarkers have anti-
inflammatory properties and that reduction of these metabolites with age may result in a 
state of chronic inflammation that has been linked to cancer. 
An experimental in-vitro study was carried out to test the effect of 
chromatographically separated GTA-rich serum on different cell lines and on 
inflammation induced cell lines compared to GTA-deficient serum. The GTA rich 
fraction showed a 40% reduction in cell viability evidenced by the detection of apoptosis 
markers such as NF-KB and Nitric oxide synthase 2. The results showed that serum 
extracts containing GTAs have anti-proliferative properties compared to GTA deficient 
extracts which seem to lack these properties (300). 
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8 SUBJECTS AND METHODS 
8.1 Objectives and Hypothesis 
The purpose of this non-randomized, multi-center study is to assess the efficacy 
of a novel serum based biomarker screening test, (Gastric tumor acid, MW=446, or GTA-
446 test), for colorectal cancer as compared against colonoscopy and pathology results. 
The effectiveness of the test will be defined by sensitivity (ability to predict CRC positive 
cases) and specificity (ability to predict CRC negative cases) under usual clinical care 
conditions. 
Specific Objectives  
 
1. Determine the correlation between GTA-446 levels and colon pathology. 
2. Comparative results of the above biomarker data with histological finds from 
pathology samples 
o No neoplasia 
o Polyps with high risk of malignancy. 
o Polyps with low risk of malignancy. 
o Cancer 
o Other conditions affecting the colon such as: ulcerative colitis and Crohn’s 
disease. 
3. Validation of Saskatchewan Disease Control Laboratory samples via replicate 
             analysis at PDI. 
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8.2 Study design 
Between June of 2008 and August 2010, 4924 subjects scheduled for colonoscopy 
were enrolled in the study at two endoscopy centers; Regina General and Pasqua 
Hospitals in Regina, Saskatchewan. 
After obtaining a written informed consent, a study nurse collected subject’s 
demographic information (including age, sex), current medical history (including liver, 
gastrointestinal diseases and cancer), family history of cancer and pathology reports of 
the performed colonoscopies. Also in the same visit, a blood sample (~10 mL) was 
collected, centrifuged and split into two tubes.  
The serum was sent frozen to Saskatchewan Disease Control Laboratory (SDCL) 
and the replicate samples were sent to Phenomenome Discoveries Inc.(PDI) after being 
depersonalized by removing all the identifying information and assigning an accession 
number. All the samples were blindly extracted and analyzed at SDCL. The 
corresponding clinical results were only released after completion of the analysis and 
release of the results. 
 
8.2.1 Study population 
Cases. Subjects consisted of males and females from age 18 to 80 years who were 
scheduled for colonoscopy at Regina General Hospital or Pasqual Hospital for any 
reason. 
Controls. Two sets of controls were used for the study; First were the Lab controls 
(N=383) which were serum samples collected from SDCL along with age and gender data, 
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Second were the Endoscopy controls (N=762) which were obtained from the colonoscopy 
population after being determined to be colonoscopy free and had no risk factors for 
developing colorectal cancer  compared to the average risk population. 
8.2.2 Analytical method and mass spectrometry analysis 
8.2.2.1 Extraction of serum samples: 
Serum samples were stored at -70˚C until time of analysis, sample preparation 
involved addition of 15.4 uL of 10ug/mL [13C1] cholic acid to 0.4 mL of serum. This was 
followed by a 4-step liquid-liquid extraction by the addition of 0.4 mL of serum with 5 
ml ethylacetate/1% ammonia solution followed by 5 ml ethylacetate/4% formic acid. 
Samples were shaken for 10 minutes and centrifuged at 3500 rpm between extractions; 
the organic layer was transferred and pooled to a new tube.  
A hundred uL of the extracted samples were injected by flow injection and 
analyzed on an API-4000 triple quadrupole mass spectrometer using negative 
atmospheric pressure chemical ionization. Multiple Reaction Monitoring (MRM) was used to 
detect and calculate raw peak areas for gamma tocoenoic acid (GTA-446) C28H46O4 (MW 446, 
445.3/383.4 [M-H] Da) and [13C1] cholic acid (MW 409, 408.3/343.4 [M-H] Da). Qualitative and 
quantitative MRM were recorded for each analyte. After the raw data was acquired, the peak 
areas for all samples were calculated using the IntelliquantTM method in the Quantitation Wizard 
module of the AnalystTM instrument software. 
8.2.2.2 Calibration curve and quality control: 
Calibration curve was prepared using serial dilutions of System Suitability 
Standard (SSS) which is ethyl acetate extract from healthy representative serum. SSS 
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serum was extracted and aliquoted by PDI so that the material used for the calibration 
curve is the same at both labs.  
SSS was diluted with ethylacetate to prepare the following SSS dilutions; 1, 0.5, 
0.25, 0.1, 0.05 and 0.01.  
Quality control material was prepared using aliquoted pooled serum that was kept 
at -70˚c until analyzed. 
On each analytical day, a single calibration curve was obtained and the quality 
control (QC) samples were analyzed. Intra-assay precision was calculated as 7% and 
inter-assay precision was 13% for the whole study. 
8.2.2.3 Calculation of the results 
Two methods were used to estimate the concentration of GTA-446 in serum 
samples; the first method was used for analysis of the samples in SDCL, it was done by 
dividing the raw peak area of GTA-446 in study samples by that of the SSS so that all 
results will be represented as a ratio level and expressed as SSS equivalent. 
The second method was used for calculation of the results at PDI (the method was 
developed later after analysis of samples has already started in SDCL). It involved the 
use of [13C1] cholic acid equivalents (CAE) as a representative of GTA-446 concentration 
which is calculated by extrapolation from a [13C1] cholic acid standard curve. 
 
9 Statistical methods: 
Statistical analysis was performed using SPSS for windows version 19 & 20.  
Plotting of ROC curve was performed using SPSS and MedCalc softwares. 
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10 RESULTS 
10.1 Patient characteristics 
Serum samples from 4924 subjects who underwent colonoscopy were collected 
along with pathology results, personal, past and family history. This allowed the 
categorization of colonoscopy population into four groups (Figure 8 and Table 3) 
 
 
 
 
Figure (8) Breakdown of the colonoscopy population into four groups. 
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Subjects with average risk  for colorectal cancer (N=1706) had to fulfill all of the 
following criteria: normal colonoscopy outcome (i.e. no polyps, inflammatory bowel 
disease or any other type of pathology), hereditary risk of CRC2 is determined to be 
average and no past or family history of CRC (302). 
Subjects whom colonoscopy results showed less than or equal to two polyps of 
benign nature, have a single 2nd degree relative CRC or have past history of uterine or 
ovarian or breast cancer were classified as intermediate risk (N=811) (303).  
Subjects were considered at high risk to develop CRC (N=2042) if at least one of 
the following criteria existed: pathology shows polyps of advanced grade of dysplasia, 
presence of inflammatory bowel disease, positive past history of CRC, positive family 
history of a first degree relative, or more than two 2nd degree relatives with CRC. The 
fourth group includes subjects confirmed by colonoscopy to have colorectal cancer 
(N=94). Two hundred and seventy one cases were not classified into one of the four 
groups due to missing one or more aspects of the clinical data. 
 
 
 
2Hereditary CRC means it is mendelian in nature- that is inherited in an autosomal dominant manner. The 
two major forms of hereditary CRC are FAB and HNPCC(304). 
                                                
2 Hereditary CRC means it is mendelian in nature- that is inherited in an autosomal dominant manner. The 
two major forms of hereditary CRC are FAB and HNPCC(301). 
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 Average Risk 
N=1706 
Intermediate 
Risk 
N=811 
High Risk 
N=2042 
Cancer Positive 
N=94 
 Males Females Males Females Males Females Males Females 
Number 728 978 370 441 928 1114 63 31 
Age in 
years(mean/Range) 55 (18-89) 57 (20-89) 58 (20-92) 65 (28-89) 
Positive for Polyps 0 620 793 0 
Positive for cancer 0 0 0 94 
Hereditary CRC 
risk 
0 0 1223 19 
Past history of 
CRC 
0 0 199 22 
Family history of 
CRC 
0 191 1416 23 
Inflammatory 
bowel disease 
(ulcerative colitis 
and crohn’s 
disease) 
0 0 220 1 
Total 4653 / 4924 
Table (3) Subject characteristics in four groups. Based on available clinical data, the 
colonoscopy populations were stratified into three risk groups; average risk group included those 
who did not have present, past or family history of CRC, and whose colonoscopy outcome was 
normal. High risk group still did not have CRC but had a risk factor of developing CRC such as 
advanced polyps, inflammatory bowel disease, positive past or family history of CRC, or high 
hereditary risk of CRC. Intermediate group includes subjects discovered with one or two polyps 
of low grade or having a single 2nd  degree relative with CRC. In addition, this table shows that 
the high risk group constituted the largest portion of colonoscopy population. Finally, the mean 
age of the three risk groups do not differ from each other while the mean age of cancer positive 
patients were significantly older than non-cancer groups. 
 
 
Figure (9) compares the mean level of GTA-446 among the four groups, the intermediate 
and high risk population did not differ significantly from the average risk population (p > 
0.5), the cancer positive group had a statistically lower mean level of GTA-446 (mean = 
0.77 SSS eq) compared to the average risk population (mean = 1.33 SSS eq, p <0.01). 
The rationale for conducting the comparison test is the expectation of finding a decline in 
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the mean level of GTA-446 as risk for developing CRC increases which was not the case 
here. 
 
 
Figure (9) Distribution of the mean level of GTA-446 in all study groups with error 
bars representing 95% confidence interval. This figure compares the mean level of 
GTA-446 in intermediate risk (mean±SD=1.6 ±0.63 SSS eq), high risk (mean±SD =1.28 
±0.62 SSS eq.) and cancer positive groups (mean±SD = 0.77 ±0.41 SSS eq.) to average 
risk population (mean±SD = 1.33 ±0.62 SSS eq.). No significant differences were found 
among the three risk groups, cancer positive patients had a significantly lower level of 
GTA-446 than average risk group (p<0.01). 
 
10.2 Correlation with age 
The average risk colonoscopy population (N=1706) was further investigated for 
the relationship between age and GTA-446 biomarker (Table 4).  A significant negative 
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correlation between age and serum GTA-446 biomarker level was found (r = -0.20) 
which confirms of what has been published before (297)). The same finding was 
reproduced examining the results from PDI (r = -0.19). 
 
Figure (10) A scatter dot diagram showing the correlation between age and 
individual serum levels of GTA-446 for SDCL average risk population. 
 
 Serum GTA-
446 values 
from SDCL 
(SSS 
equivilant) 
Serum GTA-
446 values 
from PDI 
(ug/mL CAE 
eq) 
Age at time of 
diagnosis 
Pearson Correlation -.20** -.19** 
Sig. (2-tailed) < 0.01 < 0.01 
Table (4) Correlation between age and serum level of GTA-446 for both SDCL and PDI 
data. This table shows that there is a significant decline in the level of GTA-446 in the serum as 
age increases, the Pearson Correlation coefficient examining the data from both SDCL and PDI 
are very close (r= -0.2 and -0.19) respectively, confirming this relationship. 
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10.3 Selection of controls 
Two sets of controls were used to calculate GTA-446 performance as a biomarker 
of colorectal cancer screening: Endoscopy controls and Lab controls. Endoscopy controls 
(N=762) were randomly sampled from the larger average risk population to be age 
matched to cancer positive subjects (N=94). Similarly, lab controls (N=384) were 
obtained from samples that were collected from SDCL along with age and gender data 
(N=522). Selection of controls was carried out using Fuzzy extension integrated into 
SPSS version 20 (Table 5). The rationale for choosing endoscopy controls is that they are 
considered superior to lab controls in terms of availability of clinical and pathological 
data and that they have gone through the same colonoscopy experience including the 
bowel preparation protocol as cancer-positive subjects. 
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Table (5) shows selection of endoscopy and lab controls with age, gender data and mean 
level of GTA-446 (SSS eq). This table shows that the mean level of serum GTA-446 in 
endoscopy controls (mean =1.3 SSS eq) is significantly lower than that in lab controls (mean = 
1.8 SSS eq, p < 0.01). 
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10.4 Establishment of cut-off levels for GTA-446 biomarker 
An ROC curve was plotted to calculate area under the curve (AUC) to determine 
the best cut-off value that results in an acceptable sensitivity level above 85%. The AUC 
represents the probability that the GTA-446 result for a randomly chosen positive case 
will be lower than the result for a randomly chosen negative patient, an AUC equals 0.5 
means that probability is not better than chance. 
 
Comparing GTA-446 values for cancer positive patients against lab controls 
(Figure 11) results in an AUC of 0.90 (95% CI = 0.87 – 0.92. p<0.01), choosing 1.21 SSS 
equivalent as a cut-off results in sensitivity of 87.2% and specificity of 75.5% (Table 6). 
 
Next, cancer positive subjects were compared against endoscopy controls to plot 
the ROC curve, this results in an AUC of 0.77 (95%CI = 0.74 – 0.80) and comparing it to 
the data from PDI, no significant difference was found between two AUCs (AUC from 
PDI = 0.77, 95%CI = 0.76 – 0.80, p >0.5)(Figure 12). 
 
Using the same GTA-446 cut-off value used for lab controls (cut-off = 1.21 SSS 
equivalent) to calculate test performance characteristics comparing cancer positive 
subjects to endoscopy controls results in sensitivity of 87.2% and 86.2% for data 
analyzed by SDCL and PDI respectively. Specificity drops to 49.4% and 50.3% for 
SDCL and PDI respectively. 
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Figure (11) Receiver Operating 
Characteristic (ROC) curve 
comparing GTA-446 levels in serum 
of cancer positive subjects (N=94) to 
lab controls (N=383). In this ROC 
curve, the true positive rate 
(sensitivity) is plotted as a function of 
the false positive rate (1—Specificity) 
for different cut-off points. Each point 
on the ROC curve represents a 
sensitivity/specificity pair 
corresponding to a particular decision 
threshold. Also, the ROC curve is used 
to calculate the area under the curve 
(AUC), which represents the 
probability that a cancer positive case 
will have a GTA-446 level lower than a non-cancer case. The further the curved line is 
from the diagonal reference line, the greater the probability and the discriminatory power 
of the biomarker. In this figure, AUC of the biomarker equals 0.9 which is statistically 
significant (p <0.01) (305). 
                              
 
Table (6) Summary of cut-off line, AUC with calculated test performance characteristics 
using lab controls as cancer-free subjects. Predictive values were calculated based on the 
estimated CRC prevalence of 0.03% (306). 
 
 
 
AU
C 
Positive CRC if 
less than or 
equal to Cut-off 
(SSS 
equivalent) 
Sensitivity Specificity Likelihood 
Ratio 
Predictive 
Value   
% 
95% 
CI % 
95% 
CI Pos Neg 
Pos 
% 
Neg 
% 
0.90 1.21 87.2 78.8 – 
93.2 
75.5 70.8 – 
79.7 
3.6 0.2 1 99 
 
AUC = 0.9 
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Figure (12) Receiver Operating Characteristic (ROC) curve comparing GTA-446 
levels in serum of cancer positive subjects (N=94) to Endoscopy controls (N=762) for 
SDCL and PDI data. In this ROC curve, the true positive rate (sensitivity) is plotted as a 
function of the false positive rate (1—Specificity) for different cut-off points. Each point 
on the ROC curve represents a sensitivity/specificity pair corresponding to a particular 
decision threshold. Also, the ROC curve is used to calculate the area under the curve 
(AUC) which represents the probability that a cancer positive case will have a GTA-446 
level lower than a non-cancer case. The further the curved line is from the diagonal 
reference line, the greater the probability and the discriminatory power of the biomarker. 
In this figure, AUC calculated using both SDCL and PDI data equals 0.7. 
 
 
 
 
 
 
 
 
AUC 
= 0.7 (SDCL) 
= 0.7 (PDI) 
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Table (7) Summary of cut-off line, AUC with calculated test performance characteristics 
using Endoscopy controls as cancer-free subjects.  Predictive values were calculated based on 
the estimated CRC prevalence of 0.03% (306). 
 
 
Calculating the number of cases who fall below the cut-off value of 1.21 SSS eq., 
87% of colorectal cancer patients were considered true positives compared to 50.5% and 
24.5% for endoscopy and lab controls respectively who were considered false positives 
(Table 8 ,p <0.01 after case weighting for both endoscopy and lab controls in comparison 
to cancer positive patients) . 
Comparing the group of cancer positive patients to cancer-free endoscopy 
controls, the odds of having colorectal cancer when GTA-446 is positive equals 6.7 
(95%CI = 3.6 to 12.4) and the odds ratio rises to 21 when comparing the same cancer 
positive patients to lab controls (95% CI = 10.9 to 40.2). 
 
 
 
AUC 
Positive CRC if 
less than or equal 
to Cut-off Sensitivity Specificity 
Likelihood 
Ratio 
Predictive 
Value 
% 95% CI % 95% CI Pos Neg Pos 
% 
Neg 
% 
SDCL 0.7 1.21 SSS 
equivalent 
87.2 80 – 94 49.4 45.7 - 53 1.7 0.2 1 98 
PDI 0.7 0.35 ug/mLCAE 86.2 77.5 – 
92.4 
50.3 46.7 – 
53.9 
1.7 0.3 1 98 
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 Cancer positive 
patients (N=94) 
Endoscopy controls 
(N=762) 
Lab controls  
(N=383) 
N of cases 
positive for 
GTA-446 (%) 
82  (87.2%) 385 (50.5%) 94 (24.5%) 
Pearson Chi-
Square  
X2 (1,N=856) = 45.2 
 
OR = 6.7,  p<0.01 
 
X2 (1,N=477) = 127.4 
 
OR = 21, p <0.01 
                    N=number,  OR=Odds Ratio 
Table (8) Number of cases below the cut-off (≤ 1.21 SSS eq) and considered positive for GTA 
-446. This table demonstrates that 87.2% of true cancer-positive subjects were successfully 
detected by the GTA-446 biomarker while in lab and endoscopy controls, 24.5% and 50% of 
cases respectively were found to be false positives. Using Chi-square test to compare each of lab 
and endoscopy controls to cancer -positive subjects, (OR = 21 and 6.7 respectively) that is the 
odds of having cancer in a positive GTA-446 test sample is statistically significantly greater than 
not having colorectal cancer (p<0.01). 
                
 
 
10.5 Comparison of SDCL and PDI’s results 
A strong correlation was found between GTA-446 values analyzed in SDCL 
versus those analyzed in PDI, (r = 0.82, p <0.01), and calculating true positive (TP), true 
negative (TN), false positive (FP) and false negative (FN) cases based on the established 
GTA-446 cut-off value (1.21 SSS eq for SDCL data and 0.35 ug/mL CAE for PDI’s as 
determined by their researcher) results in a kappa statistic of 0.53 and p <0.01 which 
rejects the null hypothesis that there is no agreement between both results.  
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Figure (13) Scatter dot plot showing the relation between SDCL and PDI results. 
This figure shows a correlation coefficient of 0.8 between individual GTA-446 levels for 
SDCL (SSS eq.) on the horizontal axis and PDI’s (ug/mL CAE) on the vertical axis, a 
statistically significant correlation was found (p <0.01). 
SDCL * PDI Crosstabulation 
Count SDCL Total 
FN FP TN TP 
PDI 
FN 10 0 0 3 13 
FP 0 303 76 0 379 
TN 0 82 301 0 383 
TP 2 0 0 79 81 
Total 12 385 377 82 856 
Measure of 
Agreement 
Kappa 
 
P(sig.) 
 
0.53 
 
< 0.01 
 
   
                 TP = true positive, TN = true negative, FP = false positive, FN = false negative 
Table (9) Number counts of TN, TP, FP, FN for both SDCL and PDI and kappa measure of 
agreement Using a cut-off of 1.21 SSS eq. for SDCL and 0.35 ug/mL CAE for PDI , the number 
of TP, TN, FP, and FN cases were counted and compared between SDCL and PDI’s data. Kappa 
as a measure of agreement equals 0.53 with statistical significance (p < 0.01 ) which rejects the 
null hypothesis that there is no agreement between the two sets of results. 
r = 0.8 
P < 0.01 
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10.6 PDI’s approach to data analysis 
PDI’s approach to data analysis of the study can be summarized as follow; 
• They defined the cut-off value of GTA-446 as a serum concentration falling 
within the bottom 10th percentile of reference samples (serum samples collected 
from SDCL along with age and gender data) with low age-associated risk (those 
aged 40-49, 0.35 ug/mL CAE). 
• Based on the established 0.35 ug/mL CAE cut-off value, 86% of CRC positive 
cases were calculated as true positives, they also determined the relative risk, 
based on the proportions of CRC and control cases with low versus normal GTA-
446 levels by decade of life for the reference and total colonoscopy populations 
with the assumption that the CRC incidence in the reference population would 
have been negligible.  
• Finally, they compared the CRC incidence rate among subjects undergoing 
colonoscopy with low versus normal GTA-446 levels by decade of life. 
 
It is concluded that PDI considered the current study a follow up one, and calculated 
relative risk and incidence rate to explain their results. Meanwhile, in the current thesis 
the new biomarker was validated as a diagnostic test and a screening tool for colorectal 
cancer that has been tested in a wide-scale case-control study. As a result, parameters 
such as sensitivity, specificity and odds ratio were calculated which are consistent with 
the concept of a case-control study. Both approaches are ways to analyze the data from 
two different perspectives that do not contradict each other. 
 
  
99 
 
11 DISCUSSION 
Colorectal cancer is the second leading cause of cancer death in Canada with an 
estimation of 22,200 people having developed CRC in 2011 and 8.900 who died of the 
disease (307). 
Early detection of CRC at early stages significantly improves patient outcome. 
While five-year survival rates reach 90% or higher for localized cancer, survival rates 
drop to 68% for regional cancer and 10% or less for metastatic cancer (308). 
In Canada, the five-year relative survival ratio has improved considerably, rising 
by 7.7 percentage points to reach 63% in 2006. This may be attributed to higher 
prevalence of screening in the population (307). 
Currently, the gold standard for CRC screening is colonoscopy due to its high 
sensitivity and specificity. However, colonoscopy holds several disadvantages with 
resulting poor patient compliance (309). 
On the other hand, fecal screening tests lack the sensitivity and specificity of 
colonoscopy, and they require the patient to go through an unpleasant process of sample 
collection (310). 
One strategy to improve patient adherence to CRC screening is to provide a test 
that is more convenient, minimally invasive, sensitive, and able to detect CRC at an early 
stage. Hence, there is a great need for new serum based biomarkers that fulfill the former 
criteria. 
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This study aims to validate GTA-446 as a serum based CRC screening test. Two 
sets of controls were used. The first; Lab controls (N=383) were serum samples collected 
from SDCL along with age and gender data, the second type of controls, Endoscopy 
controls (N=762) were obtained from the average risk population that were confirmed by 
colonoscopy to be pathology free and  didn’t have a higher risk of developing CRC than 
the average population.  
It was found that the mean level of GTA-446 in Lab controls is significantly 
higher than Endoscopy controls. This could be attributed to the long bowel preparation 
that endoscopy control subjects had to go through before colonoscopy. Bowel preparation 
starts one day or two before the procedure by restricting solid diet and consuming a clear 
liquid diet which should not include food coloring or fatty substance (e.g. milk or 
creamer), preparation also involves administration of laxatives and/or enema to ensure 
complete bowel cleaning and subjects are instructed to start fasting after midnight the 
night before the test (311). 
Another explanation for the difference in mean levels of GTA-446 between lab 
and endoscopy controls could be that although endoscopy control subjects were chosen to 
be free of colorectal, uterine, ovarian and breast cancer, other types of cancer were 
included which might have an effect on GTA-446 level, as the relationship between 
GTA-446 and other types of cancers have not been fully studied. Lastly, colonoscopy is 
the gold standard for CRC screening and detection, but a polyp miss rate has been 
reported especially if polyp size is small or polyp shape is flat (312). 
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 The mean level of GTA-446 was not significantly different among average risk 
(N=1706, mean of GTA=1.33 SSS eq), intermediate risk (N=811, mean of GTA=1.36 
SSS eq) or high risk population (N=2042, mean of GTA=1.28 SSS eq) but the mean level 
of GTA-446 was significantly lower in cancer positive subjects (N=94, mean of 
GTA=0.77 SSS eq) compared to the rest of the population groups which raises the 
possibility that the decline in GTA-446 is initiated by the cancer itself. This has not been 
investigated in the current study and more research is warranted.A key finding of the 
study is that serum GTA-446 was able to detect 87.2% of colorectal cancer cases at a 
specificity of 75.46% when compared to lab controls. Specificity drops to 49% when 
comparing colorectal cancer positive cases to endoscopy controls. This is expected given 
the significant difference in the mean level of GTA-446 among lab and endoscopy 
controls. In both cases, GTA-446 has a negative predictive value of over 96%. 
This is in consensus with the performance of other serum biomarkers that have 
been tested mostly in case-control studies, some of these key markers include (313); 
colon cancer specific antigen with a sensitivity of 97.3% and a specificity of 78.4% 
(314), hypermethylated gene SEPT9 (which detects multiple methyl groups attached to 
cytosine residues in the DNA) was evaluated in two case-control studies and had 
sensitivities of 68-70% and specificities of 89-90% (315;316), and two markers for 
mRNA transcripts isolated from cells circulating in the blood (Guanylate Cyclase 2 C and 
Transmembrane 4 Superfamily member 1) had sensitivities of 74% and 78.6% and 
specificities of 95.2% and 100% respectively (317;318).  
All these biomarkers have been tested in case-control studies with small sample 
size and have not been evaluated in a large population screening based study except for 
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biomarkers such as SEPT9 hypermethylation in the PRESEPT study, which evaluated the 
biomarker in a cohort study recruiting 7914 average risk subjects eligible for CRC 
screening by colonoscopy. Preliminary data from this study showed a combined 
sensitivity for three labs of 50% at 91% specificity (319). 
The current SDCL-PDI study has several strengths.. First, is the large sample size 
of the study (N=4924); these subjects were tested for GTA-446 and their results were 
compared against colonoscopy results which is the gold standard for CRC screening and 
detection. Second, all serum samples have been extracted and analyzed independently 
twice at two distant facilities, and the results showed good correlation of GTA-446 values 
(r=0.8, p < 0.01), which adds to the reproducibility of the test method. Finally, all the 
samples were blindly extracted and analyzed at SDCL. The corresponding clinical results 
were only released after completion of the analysis and release of the results, which 
eliminates the possibility of observer’s bias. 
On the other hand, the study did not address the relationship between GTA-446 
and other types of cancer or other medical conditions such as DM or the effect of fasting 
on the level of these biomarkers in blood. Given the low specificity of 49% of the 
biomarker when compared to endoscopy controls, a study looking into these associations 
is necessary. 
Also, the average risk population was selected by controlling the unmodifiable 
risk factors such as; age, presence of polyps, family history, genetic conditions(e.g. 
familial adenomatous polyposis and lynch syndrome) and inflammatory bowel disease 
(e.g. ulcerative colitis and Crohn’s disease). However, no data was collected regarding 
the modifiable risk factors to CRC such as diabetes, diet high in red meat, alcohol 
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consumption, obesity, smoking and level of physical activity. Lack of these data in an 
average risk population from whom endoscopy controls were selected should not be 
considered as a serious violation in study design as in real life situations an ideal 
biomarker should be able to detect cancer and not be impacted by other medical 
conditions. 
 
12 CONCLUSION 
Serum GTA-446 is a potential biomarker for minimally invasive detection of 
colorectal cancer that compares favorably to other serum based biomarkers. More 
research needs to be conducted to elucidate the relationship between GTA-446 and other 
medical conditions. 
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